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SUMMARY 
The blood brain barrier (BBB) is the term given to the specialized microvasculature 
of the central nervous system (CNS) responsible for the regulation of molecular transport 
into the brain from systemic circulation. While the BBB is critical for proper neuronal 
function, it also presents a significant barrier to efficient drug delivery due to its restriction 
of paracellular and transcellular molecular transport and the presence of major drug 
resistant proteins like p-glyocoprotein (Pgp). Currently available in vitro models for the 
preliminary evaluation of novel drug candidates are primarily simple, static culture models, 
which have been demonstrated to have poor predictive abilities, resulting in significant 
wastes of time and resources during subsequent preclinical and clinical studies. In recent 
years, organ-on-a-chip (OOAC) platforms have emerged as a potential means of improving 
the predictive power of in vitro assays. By allowing researchers to combine human cell 
lines with relevant chemical and mechanical cues in vitro, OOAC models provide a means 
to better balance simplicity and physiological relevance when conducting mechanistic 
studies. 
Despite a large number of increasingly complex in vitro BBB models being 
presented in the literature, no model has been adapted for widespread use in preliminary 
drug studies in place of traditional, static culture transwell systems. This can be attributed 
to a number of factors including a lack of sufficient evidence that demonstrates their 
increased predictive power over simpler models, increased cost of fabrication and 
operation, lack of ability to perform high throughput screening, and increased technical 
expertise required to establish these models. Furthermore, several key components must be 
 xvii 
integrated in the model as they contribute to the expression of BBB relevant endothelial 
cell specializations including exposure to shear stress, direct cell-cell interactions between 
relevant cell types, and a functional lumen structure.  Additionally, recent research 
indicates that proper extracellular matrix (ECM) composition is necessary for the non-
reactive culture of astrocytes, a critical cellular component for in vitro BBB modeling.  
In this work, we present a novel microfluidic lumen system of the BBB (MLS-
BBB) for the evaluation of multifunctional nanomedicines engineered for the treatment of 
medulloblastoma (MB).  Our MLS-BBB is designed to co-culture human astrocytes (HA) 
and human brain vascular pericytes (HBVP) with a cylindrical lumen of immortalized 
human brain microvascular endothelial cells (iHBMEC). Our MLS-BBB facilitates the 
administration of tunable shear rates to a lumen of endothelial cells in direct contact with 
supporting astrocyte and pericyte cells within a hydrogel system optimized to facilitate the 
appropriate culture of astrocytes, and is to our knowledge, the first model to do so. We 
employed high throughput qPCR techniques to simultaneously analyze the expression of 
81 BBB relevant endothelial specializations such as junctional proteins (ZO-1, Claudins, 
JAMs, etc.), specialized transporters (GLUT-1, CAT1, TfR, etc.) and drug resistant 
proteins (Pgp, ABCC1, ABCC4, etc.). Our results indicate that our system provides a 
marked increase in physiological relevance relative to transwell culture systems. Our 
model was further validated through comparison to BBB spheroids, by examination of 
model response to perturbations of the optimized ECM composition, and by examination 
of model response to the administration of TNFα, an inflammatory cytokine. Our model is 
currently being employed in parallel with traditional transwell systems and ex vivo brain 
slice cultures in the preliminary evaluation of a novel nanomedicine designed for the 
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treatment of sonic hedgehog driven (SSH) MB to evaluate the functional utility of the 
MLS-BBB in such studies. One of the ultimate goals of OOAC model development is 
eventual adaptation by the community for preclinical assessment of novel drug compounds. 
By combining comprehensive characterization with assessments of our model’s functional 
utility relative to standard in vitro controls, we believe our work constitutes a significant 







CHAPTER 1. INTRODUCTION AND SPECIFIC AIMS 
1.1 Objective 
The blood brain barrier (BBB) poses a significant challenge to the development of 
drugs for central nervous system (CNS) diseases due to the decrease in vascular 
permeability that results from the specialization of the endothelial cells of the BBB. The 
BBB is particularly challenging to study in vivo due to the imaging limitations posed by 
the skull and the sensitive nature and limited regenerative potential of neuronal tissue. As 
a result, a wide diversity of in vitro models of the BBB exist for the study of drug 
interaction with, and transport through, the BBB. Among these models, only simple, static 
culture assays are widely used for the preclinical assessment of novel drug compounds, 
despite increasing literature evidence indicating their poor predictive power. Thus, the 
objective of this thesis is to design, characterize, and demonstrate the utility of a novel in 
vitro BBB model for the evaluation of new drug compounds.  
1.2 Motivation 
This work is primarily motivated by the high cost and low success rate of drugs 
developed for CNS targets. The Tufts Center for the Study Drug Development estimates 
that the average drug requires an investment of approximately 2.6 billion dollars and 15 
years to develop, with over half of this investment being spent in the preclinical stages. 
Despite continuous advancements in drug screening technology and increased investment 
in drug development, the likelihood of approval (LOA) for new drug candidates (Phase 1 
to approval) is only 9.6% has remained stagnated in recent decades. When paired with 
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increasingly dire projections for the incidence of neurodegenerative diseases like 
Alzheimer’s disease (AD), the need for improved in vitro tools for the rapid and efficient 
evaluation of novel drug candidates becomes readily apparent.  
1.3 Aim 1: Development of MLS-BBB 
In recent years, OOAC devices have emerged as a potential means to increase the 
predictivity of in vitro screening tools. While many microfluidic models of the BBB are 
available in the literature, none so far have been adapted for use as preclinical screening 
tools. This can be attributed to several factors including a lack of demonstration of 
increased predictive power over simpler methodologies and the inability to facilitate high 
throughput evaluation of novel drug candidates. Furthermore, existing OOAC models of 
the BBB still lack the inclusion of one or more parameters that have been demonstrated as 
critical for the proper recapitulation of relevant BBB function such as the presence and 
appropriate culture of support cells types (astrocyte and pericyte) and the ability to facilitate 
the exposure of endothelial cells to physiologically relevant shear stress. We hypothesized 
that integration of a 3D perfusable lumen of endothelial cells in direct co-culture with 
relevant support cell types within a hydrogel system tuned mimic the ECM of brain tissue 
would result in the development of a microfluidic BBB model with increased physiological 
relevance. Hydrogel composition was tuned via the culture and subsequent analysis of 
hydrogel encapsulated human astrocytes (HA) for markers of reactive gliosis. Perfusable 
channels were created in our tuned hydrogel system using a previously described sacrificial 
element methodology, and wall shear stress was generated and maintained via pump 
facilitated gravity driven flow (PF-GDF).  BBB lumen formation was assessed via staining 
for a relevant tight junction protein (ZO-1), and multicellular architecture was visualized 
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via staining for distinct cell markers (HBMEC, CD13; HBVP, αSMA; HA, GFAP) and 
morphological observation. 
1.4 Aim 2: High Throughput Characterization of MLS-BBB 
A literature review for distinct functions of brain endothelial cells will quickly yield 
hundreds of potential targets that have been demonstrated to be either characteristically or 
differentially expressed at the BBB. However, the bulk of OOAC models of the BBB 
currently available in the literature are only characterized with a handful (~5-10) of metrics. 
Predictive ability of BBB models is largely dependent on the degree to which the 
endothelial cells can recapitulate the specializations found in BBB in vivo. Thus, we chose 
to characterize our MLS-BBB model via high throughput quantitative PCR (HT-qPCR) 
analysis of the expression of 81 BBB relevant endothelial cell specializations. In order to 
determine the relative strengths and weakness of our MLS-BBB, we also analyzed 
endothelial cells from transwell (TW) and spheroid (SP) BBB cultures. To determine 
whether our model would respond dynamically to stimulation, we also assessed the 
response of our MLS-BBB model to inflammation via administration of TNFα. Lastly, we 
examined the effect of perturbations to the ECM composition on the expression of BBB 
relevant specializations in our MLS-BBB system.    
1.5 Significance  
This work constitutes a significant contribution to the fields of tissue engineering and 
OOAC research by producing the first (to our knowledge) in vitro model of the BBB 
capable of simultaneously incorporating a perfusable lumen of endothelial cells in direct 
contact with both astrocyte and pericyte cells within a hydrogel system tuned to facilitate 
 4 
the appropriate culture of astrocytes. Furthermore, through the comprehensive 
characterization of our model, we have produced a body of evidence that facilitates direct 
comparison of the performance of our MLS-BBB to other commonly used in vitro BBB 
models for a wide range of BBB relevant endothelial cell specializations. It is our hope that 
such validation will contribute to the growing body of evidence demonstrating the 
inferiority of currently used models and encourage more widespread experimentation with 
and adaptation of OOAC models in the preclinical assessment of novel drug candidates.    
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CHAPTER 2. BACKGROUND 
2.1 Motivation 
As stated, the objective of this thesis is to design, characterize, and demonstrate the 
utility of a novel in vitro BBB model for the evaluation of nanomedicines engineered for 
the treatment of MB. This work is primarily motivated by the high cost and low success 
rate of drugs developed for CNS targets. The Tufts Center for the Study Drug Development 
estimates that the average drug requires an investment of approximately $2.6 billion and 
15 years to develop, with over half of this investment being spent in the preclinical stages. 
Despite continuous advancements in drug screening technology and increased investment 
in drug development, the LOA for new drug candidates is only 9.6% and has remained 
stagnated in recent decades [1].  
There are many challenges in the drug development pipeline that contribute to this high 
probability of failure in clinical trials, ultimately culminating in a drastic increase in 
healthcare spending. Healthcare spending now accounts for 17% of GDP in the United 
States [2], and in cases of diseases like cancer, this cost burden often gets shifted to the 
patient. In 2012, twelve out of the thirteen novel cancer drugs approved by the FDA were 
priced at over $100,000 annually, creating a significant financial burden for patients [3]. 
This pricing is particularly disturbing considering that cancer treatment often involves a 
combination of multiple chemotherapeutics, radiation treatment, and surgery [4]. 
Improvements in the drug development pipeline are critical to the mitigation of such costs 
to society and individuals.  
 6 
The high cost associated with such drugs and their development is multifactorial in 
origin. Many critics cite redundancies in clinical trials between competing pharmaceutical 
companies, lack of information and data sharing between competing pharmaceutical 
companies, and inflated price valuation by pharmaceutical companies as major factors [3], 
but the high cost of development is also thought to be largely due to the lack of predictive 
screening tools available for the preclinical assessment of novel drug candidates leading to 
failures in human clinical trials [5]. 
Clinical trial failures most typically result from the inability to demonstrate efficacy 
(56%) or the presentation of adverse drug events (28%) [6], indicating that current 
preclinical assessment is not sufficiently robust to remove poor drug candidates prior to 
investment in human clinical trials. Several techniques exist for the preclinical evaluation 
of new drug candidates including computer modelling techniques (in silico), testing with 
cultured cells (in vitro), and evaluation in animal models (in vivo). Currently, new drug 
candidates are identified from a library of potential compounds and evaluated in static cell 
culture before being evaluated in vivo in an animal model. While static culture assays are 
a necessary first step in evaluation of new compound toxicity, such simple assays are 
unable to accurately capture the complexity of in vivo response and often yield results that 
are not predictive of animal model or human patient response. Furthermore, in vivo 
validation can often be convoluted by organism complexity and the physiological variation 
between the study animal and a human patient.   
In response to these challenges, the field of tissue engineering has produced a number 
of OOAC model systems that are particularly promising candidates for incorporation into 
preclinical drug assessment workflows [7]. These devices aim to improve the predictivity 
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of preclinical assessment by allowing for the culture of human cells in more physiologically 
relevant microenvironments. Such OOAC devices have demonstrated the potential to serve 
as more predictive early stage screening tools that can efficiently evaluate new drug 
compounds, and it has been widely speculated that the modification of preclinical 
assessment to include OOAC validation will lower developmental costs, accelerate 
developmental timelines, and increase affordability of new drug products. 
 
Figure 1. Preclinical assessment of novel drug compounds. (A) The drug develpoment 
pipeline can be broken down into four stages: basic research, pre-clinical research, clinical 
evaluation and post market study (B) A number of in vivo, in vitro and in silico techniques 
are available for use in preclincal evaluation and in recent years in vitro validation has 
expanded to include validation via OOAC models (C) Current preclinical assessment 
worflow (D) Proposed integration of OOAC models into preclinical assessment.  
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2.2 Organ-on-a-Chip Models (OOAC) 
OOAC platforms have arisen from the fields of microchip manufacturing and tissue 
engineering research as a potential improvement to existing preclinical screening tools [8, 
9]. OOAC models are in vitro cell culture platforms that are created by microchip 
manufacturing methods to house living cells in relevant multicellular architectures within 
a perfusable culture chamber.  OOAC models aim to bridge the gap between static cell 
culture systems and animal models by leveraging advances in microfluidic technology and 
3D tissue engineering to create simple, but predictive, screening platforms that better 
recapitulate innate in vivo physiology while readily facilitating detailed mechanistic 
observation. By allowing researchers to combine human cell lines with relevant chemical 
and mechanical cues in vitro, OOAC models provide a means to better balance simplicity 
and physiological relevance when conducting mechanistic studies [10]. 
2.2.1 Comparison to In Vitro and In Vivo Models 
While OOAC models are still far from displacing animal studies or simple cell 
culture assays in the drug development process, OOAC models could carve out their own 
niche in the drug development pipeline as they provide several distinct advantages over 
both in vitro and in vivo systems for preliminary drug studies (Table 1). For example, 
OOAC models readily facilitate the incorporation of relevant chemical and mechanical 
cues that simpler in vitro models lack. By recapitulating proper multicellular architecture, 
incorporating perfusable vasculature, and tuning to proper physiochemical 
microenvironments, OOAC devices have been used to replicate aspects of tissue and organ 
level functionality that are not achievable in conventional 2D or 3D in vitro cell culture 
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systems [11]. Furthermore, in addition to being much more cost effective than animal 
studies for early stage evaluation, OOAC models enable the use of human cell lines and 
proteins, which helps to minimize the gap in translation that can arise from species to 
species variation during in vivo validation. OOAC models also allow for real time 
monitoring of target systems and enable detailed mechanistic study of organ systems and 
transport phenomena that cannot always be easily imaged in vivo (brain), allowing 
researchers to gain insight into time dependent processes that would be obscured in an 
animal model in which sometimes only end point data can be collected [10-14]. 
Table 1. Comparison of in vitro, in vivo and OOAC model capabilities.  
 
2.2.2 Economic Justification for Development of OOAC BBB Models 
As noted, the development of new drugs is an expensive and time-consuming 
process. Neurological and oncology drugs are even less likely to succeed in clinical 
development, with LOAs of 8.4% (n=1304) and 5.2% (n=3163), respectively. These 
probabilities of success are significantly lower than other disease areas such as 
haematology (26.1%, n=283), infectious disease (19.1%, n=916), respiratory (12.8%, 
n=428), and gastroenterology (15.1%, n=156), indicating a particularly dire need for 
improvements to early stage screening tools for the evaluation of CNS drug candidates [1].  
 10 
When combined with projection figures for increasing incidence of 
neurogenerative diseases such as AD, which is estimated to affect as many as 13.2 million 
people by 2050, the urgent need for better preclinical screening tools for CNS pathologies 
becomes evident. The cost for caring for AD patients in America is projected to total $259 
billion in 2017. Medicare ($131 billion) and Medicaid ($44 billion) programs, programs 
largely funded by taxpayers and their employers, bear the majority of this expense [15]. 
While the primary focus of this work is the development of a BBB model for the evaluation 
of brain cancer therapeutics, the BBB poses an additional challenge to the development of 
any neurological therapeutic. The production of better screening tools for CNS compounds 
will help to accelerate the drug development pipeline, decrease the cost of treatments, and 
could also play a significant role in mitigating the cost to society posed by high incidence, 
debilitative neurological pathologies like AD. 
2.2.3 Current Status and Challenges 
Promising OOAC models have been developed for a number of organ systems [16] 
including lung [11, 17], liver [18, 19], heart [20, 21], intestine [22-24], kidney [25-29], 
bone marrow [30], skin [31-33], and brain [34, 35]. While many of these devices have 
demonstrated significant improvements over traditional in vitro culture systems, with the 
exception of liver-on-a-chip, lung-on-a-chip, and kidney-on-a-chip, many have yet to be 
adapted widely in the scientific community due to several key challenges [7, 8, 12, 36]. 
OOAC models can be costly to fabricate and operate, often requiring cleanroom facilities 
and technically trained personnel. Additionally, OOAC models are rarely conducive to 
high throughput studies, a capability that is necessary for adaptation by the pharmaceutical 
development industry. Researchers cite many other technical challenges including: 
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standardization of models, difficulty maintaining mechanical and chemical cues (pressure 
and solute balance within chips), difficulty integrating non-destructive monitoring 
capabilities such as trans endothelial electrical resistance (TEER) electrodes, and difficulty 
recovering cells from chips for downstream experimentation or analysis [12].  
In addition to these unresolved challenges, the establishment of a functional, 
perfusable, vasculature component is technically challenging to repeatedly achieve in vitro.  
However, due to the ubiquitous need to vascularise tissue constructs for long term 
experimentation, several techniques have emerged in the literature that enable the reliable 
formation and perfusion of vascular constructs within microchip platforms. These methods 
are discussed in the immediately ensuring sections. OOAC models of the BBB have their 
own distinct requirements and challenges that are discussed in more detail in the ensuing 
sections and are summarized in Table 3. Despite these challenges and current limitations, 
OOAC models have already demonstrated the potential to improve the drug discovery and 
drug development process and have garnered renewed and increased investment by 
research institutions (NIH/NCATS, NSF, CASIS, DARPA, FDA) and the pharmaceutical 
industry in recent years [36, 37].  
2.2.4 Incorporation and Perfusion of Vasculature in OOAC Devices 
The establishment of functional and perfusable vasculature for nutrient delivery to 
OOAC devices is essential to the successful development of any OOAC device and is 
especially critical for the fabrication of a BBB-on-a-chip device. While no gold standard 
practice currently exists for the fabrication of vasculature within OOAC devices, the 
ubiquitous need to vascularize tissue constructs for long term study has resulted in the 
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establishment of several methods for the formation and perfusion of vasculature within 
OOAC systems. These methods can be broadly categorized into prevascularization based 
techniques and vasculogenesis and angiogenesis based techniques [38-41].  
Prevascularization based techniques include subtractive methods such as the 
incorporation and dissolution of a sacrificial element [42, 43], viscous fingering [44],  and 
needle based molding, as well as additive methods such as soft lithography and PDMS 
stamping techniques [45, 46], layer by layer stacking [47], hybrid methods involving micro 
milling and lithography techniques [48],  bioprinting [49-51], and image based laser guided 
techniques [52-54].  
Angiogenesis and vasculogenesis based techniques leverage the natural capabilities 
of cells to form microvessel constructs. Angiogenesis refers to the formation of new blood 
vessels from existing blood vessels and vasculogenesis refers to the differentiation of 
precursor cells into endothelial cells and ensuring formation of a primitive vascular 
network [55]. Photolithography techniques can be used to create PDMS housings whose 
geometry facilitates the endogenous formation of microvessels either by vasculogenesis or 
angiogenesis. Additionally, angiogenesis and vasculogenesis can be accomplished via the 
administration of growth factor gradients to cells [56], through the use of functionalized 
biomaterials, via the co-culture of multiple cell types [57] or via a combination of these 
methods [40].   
While many of these methods have been under active investigation discussion in 
the community for many years, the technical difficulties surrounding the more 
sophisticated methods, such as the bioprinting and image guided laser techniques, were 
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still substantial at the inception of this work. Thus, we chose to adopt a sacrificial element 
method for use in our work due to the simplicity and customizability of the workflow [42].  
 Once a vascular construct is established, media perfusion can be initiated and 
controlled in a variety of ways. Pressure gradients can be driven by gravity, surface tension, 
osmosis, or by direct infusion or withdrawal via syringe pumps. Peristaltic pumping, 
centrifugal pumping, electrokinetic pumping and electroosmotic pumping have also been 
used to drive flow through microfluidic devices [58]. Each of these methodologies has its 
own distinct capabilities, advantages, and disadvantages that are briefly summarized in 
Table 2. For our study, we originally planned to use syringe pumps to generate flow 
through our MLS-BBB; however, this proved impossible due to the low mechanical 
strength of the hydrogel used, the tendency of bubbles to form on the surface of the housing, 
and the propagation of mechanical disturbances from the syringe pump to the MLS-BBB 
device. As a result, we used a modified version of gravity driven flow to facilitate the long 
term, stable, perfusion of our devices. Specific details of flow generation using this method 
can be found in Section 3.2.5.  
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Table 2. Comparison of pumping methodologies used to drive flow through 
microfluidic chips. 
 
2.3 The Blood Brain Barrier (BBB) 
To successfully recapitulate the BBB on a chip, is it necessary to first examine the 
relevant anatomy (structure) and physiology (function) of innate human BBB. The BBB is 
challenging to study in vivo, and many aspects of BBB physiology remain convoluted and 
under investigation by the scientific community. The following sections present a 
condensed overview of the current literature available on the biology of the BBB, with 
emphasis placed on the impact of cellular architecture and ECM composition on the 
function of the system, followed by a summary of existing in vitro, in vivo, and in silico 
models of the BBB with a discussion of their relative strengths and weaknesses.  
2.3.1 Distinct Biology of BBB Endothelial Cells 
The BBB is the term given to the anatomically specialized endothelial cells that 
make up the microvessels of the CNS. The BBB protects sensitive neuronal tissue from 




Osmosis Syringe Vacuum Peristaltic Electric Centrifugal
Potential for surface fouling Low Moderate Low Low Low Low High Low
Potential for mechancial disturbances Low Low Low Moderate Moderate Moderate Low Moderate
Potential for chemical disturbances Low Low Moderate Low Low Low Moderate Low
Potential for electrical distrubances Low Low Low Low Low Low High Low
Ability to facilitate microscopy Yes Yes Yes Yes Yes Yes Yes Yes
Ability to facilitate media recirculation Moderate No No No No Yes Moderate No
Ability to generate pulsatile flow No No No Yes No Yes Yes Moderate
Ability to generate steady flow Moderate No Yes Yes Moderate Moderate Moderate Moderate
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by restricting the influx of systemically circulating ions and neurotransmitters, while 
allowing for immune surveillance with minimal inflammation [59].  In contrast to the 
unlined microvessels that exist elsewhere in the body, the microvessels of the brain are 
composed of endothelial cells that are lined abluminally by pericytes and wrapped by 
astrocytic end feet [60]. The endothelial cells of the BBB are highly specialized [61-65] 
and are characterized by the differential expression of a number of proteins [63, 66]. For 
example, BBB endothelial cells have an increased expression of tight junctions between 
neighboring cells that greatly limits the paracellular diffusion of polar molecules [67-69]. 
Additionally, the endothelial cells of the BBB have a decreased number of fenestra and 
pinocytic vesicles, resulting in limited transcellular trafficking. Thus, essential molecules 
are largely transported via a variety of specialized transcellular pathways (Figure 2). Large 
or nonpolar molecules that cannot exploit one of these transcellular pathways cannot enter 
the brain [70, 71]. It has been estimated that these specializations limit the transport of up 
to 98% of molecules, constituting a significant hurdle for drug delivery [72].  
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Figure 2. Available routes of transport across the BBB. Small, non-polar, lipid soluble 
compounds can passively diffuse through endothelial cell membranes into the cytoplasm 
(1) Carrier molecules chaperone necessary compounds (3) and remove unwanted 
compounds from the cytoplasm (2). Large, polar, molecules that cannot passively cross the 
lipid bilayer of the cell membrane are transported by either receptor mediate transcytosis 
(RMT) (4) or adsorptive mediated transcytosis (5). Very small polar molecules can 
passively diffuse through the tight junctions connecting neighbouring endothelial cells (6). 
2.3.2 The Neurovascular Unit (NVU) 
In order to understand how the BBB will respond to stimuli, it is critical to 
understand the underlying structure that contributes to proper endothelial barrier function. 
The neurovascular unit (NVU, Figure 3) is the functional unit of the BBB and is composed 
of five cell types that work together to regulate transport and maintain the homeostatic 
environment necessary for optimal neuronal function. It is the proper function of the 
multicellular NVU, as opposed to endothelial cells alone, that is critical for the maintenance 
of BBB barrier integrity [73-75]. One feature to note is that the cellular architecture of the 
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NVU changes at different levels of circulation (arteries  arterioles  capillaries) where 
the vasculature performs different functions. At the arteriole level, the NVU is most 
relevant to metabolism, rather than molecular transport, and is critical for regulating 
dilation and contraction of vessels in response to increased brain activity [59, 71]. It should 
be noted that the scope of this work is limited to the study of the BBB and NVU at the 
capillary level of circulation, the primary site of drug delivery, nutrient transport, and waste 
removal in tissue. Thus, all references to BBB or NVU are in reference to capillary BBB.  
 
Figure 3. Cellular composition of the neurovascular unit. Distinct cellular architecture 
characterizes the BBB at different levels of circulation, enabling specialization to facilitate specific 
tasks (bulk transport of blood vs. molecular transport). At the capillary level, the endothelial cells 
of the BBB are connected via tight junctions and are partially surrounded by pericyte cells that 
provide structural support and are largely responsible for the secretion of the ECM proteins that 
comprise the shared pericyte and endothelial basal lamina. Astrocytic end feet encircle the 
microvessel wall and provide a link to neuronal activity. Microglia, specialized brain immune cells, 
serve as the first line of defense against toxic compounds or bacteria that are able to cross the BBB. 
When harvested and cultured in 2D cell culture, brain endothelial cells rapidly de-
differentiate and lose their “BBB-like” properties [76]. It has been well documented that 
exposure to astrocyte cells can facilitate the partial recovery of certain BBB relevant 
endothelial cell specializations by stimulating the increased expression of junctional 
proteins between neighboring endothelial cells [60] and, until recently, many researchers 
considered the presence of astrocyte cells or astrocyte conditioned media as sufficient for 
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the maintenance of the specialized endothelial microvessels of the BBB. However, in 
recent years it has become evident that correct endothelial cell differentiation and function 
relies on the proper multicellular local environment and its surrounding ECM [76-80].  
This work has chosen to narrow the scope of study to focus on endothelial, 
astrocyte, and pericyte cells for the first iteration of our MLS-BBB device as literature 
evidence indicates that these three cell types are most directly related to barrier function. 
Contact of astrocyte endfoot projections with endothelial cells provides the trophic cues 
necessary for the expression of tight junction proteins between endothelial cells that restrict 
paracellular diffusion. Additionally, astrocytes secrete chemical factors that can modulate 
the permeability of the endothelial cell layer (and to a lesser degree, dilation of 
microvessels) in response to neuronal stimulation [60]. Pericyte exposure provides the 
necessary stimuli for BBB appropriate surface receptor expression levels that allow brain 
endothelial cells to selectively uptake compounds via transcellular pathways. Pericytes also 
play a central role in structural organization of endothelial cells by synthesizing and 
secreting most elements of the basement membrane (an approximately 40nm thick layer of 
collagen IV, laminin, and fibronectin), thereby aiding in barrier stabilization and 
polarization. Pericytes have also been implicated as necessary for BBB embryogenesis, 
regulation of blood flow in capillaries, and successful angiogenesis [78, 80, 81]. All three 
cell types (endothelial, astrocyte, and pericyte) are intrinsically programmed to respond to 




2.3.3 Extracellular Matrix Composition of the Brain and BBB 
Brain ECM is different from ECM of other tissues in several ways. In general, the 
ECM of the brain contains relatively small amounts of fibrous proteins (collagens, 
fibronectin) that constitute the bulk of other ECMs and comparatively high amounts of 
glycosaminoglycans, both bound to proteins (proteoglycans) and unbound (hyaluronan). 
ECM composition varies spatially in the brain and can be broken down into three general 
compartments for a simplified introduction: the basement membrane or basal lamina, the 
perineuronal nets, and the neural interstitial matrix. The basement membrane is a thin 
boundary layer separating the endothelial cells of the BBB from parenchymal tissue and is 
composed largely of collagen IV, entactin (laminin-nidogen complexes), dystroglycan, 
perlecan, and fibronectin. The perineural nets surround neuronal cell bodies and proximal 
dendrites and are composed largely of proteoglycans, tenascin R, and link proteins. The 
neural interstitial matrix is a dense network of hyaluronan, proteoglycans, tenascins, and 
link proteins. Select fibrous proteins and adhesive proteoglycans are also present in small 
amounts in the neural interstitial matrix [83].  
The ECM of basement membrane is most relevant to this work, but attention should 
also be paid to the ECM composition that is most relevant and appropriate for astrocyte 
culture (neural interstitial matrix), as astrocytes influence the endothelial cells of the BBB 
via endfoot contact. Additionally, it has been demonstrated that suboptimal culture of 
astrocytes results in astrocyte activation to a reactive gliosis state [84]. While activated 
astrocytes do a play a role in responding to and repairing damaged brain tissue, activation 
has also been shown to cause neuronal damage and has been implicated in the progression 
of a number of disease states [85-88]. Thus, when considering ECM composition for the 
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creation of a physiological BBB model, it is essential to balance the needs of astrocyte cells 
with those of the endothelial cells or the result is likely to be a pathophysiological rather 
than physiological model. 
2.3.4 Challenges to Drug Delivery and Potential Solutions 
While the BBB is critical for proper neuronal function, it also presents a significant 
barrier to efficient drug delivery to brain tissues due to its restriction of paracellular and 
transcellular molecular transport and the presence of major drug resistant proteins like Pgp 
[89]. The BBB is virtually impossible to study in human patients due to the sensitivity and 
limited regenerative potential of neuronal tissue and the imaging and monitoring 
limitations posed by the skull.  As a result, a plethora of model systems (in vitro, in vivo, 
in silico) exist for preliminary examination of BBB drug penetrance and are discussed in 
more detail below. Experimentation with these models has yielded insight into BBB 
structure and function and has led to the development of a few techniques to increase drug 
permeance into the brain such as disruption with ultrasonic microbubbles [90] and osmotic 
infusion [91]. Osmotic infusion based techniques are invasive, requiring direct 
intracerebral or intraventricular injection, and both methods necessitate the temporary 
disruption of the BBB, creating an opportunity for injury, infection, toxicity, and spatially 
variable drug delivery. 
In contrast to the brute force efforts of osmotic infusion and ultrasonic cavitation, 
olfactory transport has been proposed as a potential means to bypass the BBB entirely by 
direct administration to the nasal endothelium and ensuing transport into the brain via the 
olfactory nerves [92-94]. Intranasal delivery is currently used in approximately 2% of 
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dosing protocols for commercially available drug products. Among these products are 
hormone replacement therapies (estradiol), pain management drugs (butorphanol, 
sumatriptan, zolmitriptan) and allergy medications (fluticasone) [95, 96].  However, the 
practical application of this delivery route is limited to a restricted pool of drugs and target 
delivery sites due to the sensitivity of the nasal epithelium, the small volume of the nasal 
cavity, potential for mucociliary drug clearance, and the potential variance in dosing 
resulting from fluctuating pH of the mucosal membrane of the nasal epithelium. It has been 
demonstrated that some of the dosing restrictions that result from the sensitivity of the nasal 
epithelium and restricted volume of the nasal cavity can be mitigated by the encapsulation 
of drugs in nano-scale drug delivery systems. Such nanomedicines have been shown to 
enhance the delivery of intranasal drugs. However, delivery of therapeutically relevant 
doses to the brain via nasal administration has yet to be successfully demonstrated in 
humans [96]. 
To date, no existing techniques or therapies can either circumvent or reversibly alter 
the BBB at a specific site without compromising the integrity of the system. As a result, 
many researchers have devoted study to the development of biologically or chemically 
engineered compounds that can act as “Trojan horses” to escort payloads across the BBB. 
Endogenously transported compounds are limited to gases (oxygen, carbon dioxide, etc.), 
metabolic products (glucose, etc.), hormones (estrogen, etc.), and small neutral lipophilic 
compounds. Several studies indicate that passive transport of nanoparticles (NPs) can be 
achieved at sizes below 15nm [97], leading researchers to speculate on the potential of 
nanoscale drug delivery vectors as a means to shuttle compounds across the BBB [98]. 
Particles between 15nm and 100nm also have potential to penetrate to the brain, but uptake 
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efficiency decreases exponentially with increasing size. This decrease can be partially 
mitigated via modifications to the surface of the NP to increase lipophilic properties and 
reduce surface charge.  It has been demonstrated that when systemically administered, 
these small, neutral lipophilic particles bind with endogenously circulating lipoproteins 
like apolipoprotein E (ApoE), which then help to chaperone the particles across the BBB. 
Additionally, particles can be engineered to contain monoclonal antibodies to exploit 
known routes of transport via receptor mediated transcytosis (RMT) [99].  A 
comprehensive review of the current state of the art of nanomedicine is outside the scope 
of this work, but more information on the interactions of NPs with the BBB and a 
discussion of NP platforms used in this and closely related studies is included in the ensuing 
sections for additional context.  
2.3.5 In Vivo Methods for Studying the BBB 
There are several methodologies and metrics available for the study of the BBB and 
the quantification of drug penetration in vivo. The two most widely used methods are the 
ratio of steady-state concentration of a compound in the brain to concentration in the blood 
(logBB) which is used to determine the extent of brain penetration by a drug, and the 
measurement of permeability by surface area (PS) that is used to determine the rate of brain 
penetrance. Other methods of study include knock out or gene deficient animals, and 
microdialysis for the determination of free drug concentration in the brain. For many 
targets, free drug concentration (unbound to brain lipids and off target sites) is the most 
critical metric for evaluating dosage parameters. Due to the technical difficulty of 
microdialysis methods, the ratio of cerebrospinal fluid (CSF) drug concentration to plasma 
drug concentration can be used in some cases as a metric to approximate the concentration 
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in interstitial brain fluid. While these models and methods do yield substantial information, 
the in vivo methods for studying drug interaction with the BBB are technically difficult to 
perform and low throughput do to the limitations imposed by the relatively small size of 
study animals (mice, rats) and limited access to target tissues. As a result, much of the early 
stage evaluation of new drug candidates for BBB crossing ability is carried out first in in 
vitro models or via in silico modelling [100]. 
2.3.6 In Silico Methods for Studying the BBB 
In the last few decades, improvements in computing technology have revolutionized 
every branch of science, and there has been considerable interest and effort devoted to 
building computational models that will be able to predict drug interaction with and 
transport across the BBB. Computational prediction relies on large datasets to build robust, 
predictive models. Such modelling efforts for the BBB were originally limited by a lack of 
minable datasets. For example, the largest logBB dataset available for study in 2003 only 
consisted of about 150 compounds.  Despite this limitation, early models built using these 
resources led to the generation of several general “rules of thumb” for designing drugs with 
BBB crossing abilities and were able to successfully predict penetrance for ~80% of tested 
compounds [101]. More recently, in silico modelling methods have been created for more 
specific examinations (e.g. nanoparticle specific interactions with the BBB) and have 
contributed support to the field through modelling of quantitative structure-activity 
(QSAR) or structure-property (QSPR) relationships, molecular metabolism, molecular 
docking, and molecular dynamic simulations to predict absorption, distribution, 
metabolism, excretion, and toxicity (ADMET) properties [102]. 
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2.3.7 Cell Free Methods for Studying the BBB 
Due to the many challenges of modeling the BBB both in vivo and in vitro, a 
number of creative solutions have been attempted in the field over the years. One such 
example is the development of high performance liquid chromatography columns 
composed of immobilized artificial membranes (IAMs) that were engineered to have 
properties similar to biological membranes. Despite the complete lack of biological 
components, some of these attempts were moderately successful at ranking compounds 
according to BBB permeability but were not adaptable to high throughput operations [100]. 
 Another cell free technology that can be used to study the BBB is the parallel 
artificial membrane permeability assay (PAMPA). Originally developed as a surrogate to 
predict gastrointestinal absorption, the PAMPA system has been successfully used for 
predicting the permeability of drugs across other biological barriers. By altering the lipid 
content and composition of the artificial membranes, PAMPA has been demonstrated to be 
capable of predicting drug permeability across the BBB with a reasonable degree of 
accuracy [103]. 
2.4 In Vitro Models for the Study of the BBB 
In addition to available in vivo, in silico, and cell free BBB models, a multitude of in 
vitro models of the BBB are available for the preliminary evaluation of novel drug 
candidates. These models range in complexity from simple, static, mono-culture systems 
to 3D multicellular constructs within microfluidic chips that integrate flow and on-board 
barrier monitoring capabilities.  As discussed above, the function of the BBB is heavily 
dependent on properties of its structural composition, both cellular and extracellular. As 
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such, there are a number of specific requirements for a BBB model to be considered 
functional and accurate: cell to cell interactions leading to proper cellular architecture [82, 
104], the expression of tight junctions between endothelial cells, relative exposure to 
promoting factors, exposure to physiologically relevant flow, and appropriate endothelial 
cell surface receptor expression [105, 106]. Additionally, to be useful in the context of drug 
discovery and the evaluation of new drug candidates, the model needs to be able to be 
replicated easily and reliably and would ideally facilitate adaptation to a high throughout 
platform [5, 107]. While many in vitro models exist in the literature [108-118] (recent 
examples summarized in Table 3), none currently incorporate all the necessary stimuli for 
proper BBB formation and maintenance. Presented below is an overview of the most 
common sub types of in vitro BBB models: static 2D culture systems, “organoid” systems, 
and microfluidic systems. Due to the diversity of microfluidic designs, microfluidic models 
are further broken into microfluidic transwell systems (μF-TW), and microfluidic lumen 
systems (μF-L) for discussion.  
2.4.1 Static 2D Culture Systems 
Static culture systems are the most commonly used model for preliminary analysis 
of BBB drug interaction in vitro due to their affordability, simplicity, and high throughout 
capabilities. Brain endothelial cells (both primary and immortalized cells have been 
sourced from various origins including human, rat, mouse, etc.) are commonly used for 
early stage evaluation of toxicity. Transwell plates in which cells are cultured on a semi-
permeable polycarbonate membrane suspended between two media reservoirs are also a 
common tool for preliminary drug screening due to their ability to co-culture up to three 
cells types simultaneously, ability to perform non-destructive barrier measurements via 
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TEER electrodes, and ability for high throughput scale up [119]. Transwell tri-cultures of 
endothelial, astrocyte and pericyte cells have recently become more common in the 
literature [82], and while they do provide advantages to mono-culture systems (more 
appropriate junctional and surface receptor expression is mediated by presence of 
astrocytes and pericytes, respectively), they are limited in their ability to recapitulate in 
vivo physiology due to the lack of direct cell contact between cells types limiting cell to 
cell signalling to that which can be accomplished via the diffusion of soluble factors and 
the absence of flow, a critical for proper endothelial cell differentiation [120].  
2.4.2 Organoid Culture 
It is well established in the literature that 3D culture is superior to 2D culture in 
vitro. In vivo, cells respond to a number of cues including mechanical and chemical 
stimulation from the surrounding cells and ECM [121]. Spheroid culture techniques 
emerged in the 1950s as one of the first 3D cell culture systems. While they were originally 
used for the study of tumor aggregates, spheroids have been applied to many other organ 
systems. Multicellular spheroidal BBB (SP) models are simple to make, requiring only the 
three cell types (and appropriate cell culture reagents), a multichannel pipette, and an 
agarose coated round bottom well plate (or hanging droplet culture plate). When co-
cultured in suspension within an appropriate plate, astrocyte, pericyte, and endothelial cells 
will spontaneously arrange into spheroids with a physiologically relevant distribution of 
cells. Astrocytes localize in the core, pericytes localize in the middle, and endothelial cells 
line the outside of the spheroid. Flow cytometry analysis of endothelial cells from these 
cultures has further supported literature evidence that indicates the expression of key 
receptors relies on direct contract with both astrocyte and pericyte cells simultaneously. 
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Exclusion of either cell type, or sequential exposure of all cell types decreased the degree 
to which endothelial cells mimicked in vivo properties [82]. Spheroids provide several 
advantages over other in vitro models due to their ability to facilitate direct contact and 
appropriate arrangement of relevant cell types in 3D, ease of scale up, affordability, and 
simplicity. Spheroid cultures are not capable of facilitating TEER measurements, but they 
can be monitored via optical and fluorescent miscopy throughout experimentation. In 
addition, BBB spheroid cultures are not currently able to incorporate flow, but studies to 
accomplish such culture systems using microfluidics are underway in the scientific 
community for other organ systems and could be readily adapted to the culture of BBB 
spheroids [35, 82, 122].  
Other “organ level” assays available for the study of the BBB include commercially 
available angiogenesis assays (Corning Matrigel). In these assays, brain endothelial cells 
can be cultured alone or in combination with relevant support cells and evaluated using 
standardized assay metrics. These models are of particular use to the study of the blood 
tumor barrier (BTB) and the evaluation of anti-angiogenic chemotherapeutics. Like 
spheroids, these simple and affordable assays are capable of scale up and readily facilitate 
microscopic monitoring in a format that allows for the direct cell contact of relevant cell 
types in a 3D microenvironment. However, the microtubule structures formed by such 
assays are not perfusable and cannot be used for permeability or drug transport studies, 




2.4.3 Microfluidic Culture of the BBB 
As discussed above in the review of OOAC models for drug discovery and 
development, recent advancements in microfabrication technologies have enabled the 
emergence of microfluidic culture systems for the study of many organ systems, including 
the BBB. Microfluidics allow researchers the ability to precisely control the 
microenvironment in a spatial and temporal fashion that cannot be accomplished with other 
in vitro systems. Additionally, microfluidics enable the culture of cells in more relevant 
dimensions (i.e. micro- vs. milli-) [106]. Despite a large investment into the development 
of in vitro BBB devices, no physiologically relevant in vitro BBB models currently exist.  
Major challenges lie in the integration several key components that maintain the key 
functionality and physiological relevance: endothelial cell specialization in response to 
shear stress [120, 124], direct cell-cell interactions between cells types [82, 125], and 
appropriate lumen geometry [104]. Recent publications in the field have made progress in 
addressing these issues individually, but none so far have been successful in the 
simultaneous incorporation of these parameters. Additionally, none of the currently 
published in vitro BBB models take the composition of the ECM into consideration during 
design, despite significant evidence that ECM composition can impact the health and 
relevant culture of NVU cell types [84]. Due to the dire need for better in vitro BBB 
screening tools, a number of different techniques have been employed in an attempt to 
integrate these key components into a single system, resulting in a diversity of microfluidic 
models of the BBB in the literature [108, 110, 112, 116, 118, 126-128].  
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2.4.3.1 Microfluidic Transwell Models of the BBB (μF-TW) 
As the name implies, microfluidic transwell systems are microscale adaptations of 
transwell culture systems. Although some single layer devices exist, these devices are 
typically multi-layered microfluidics, resulting in increased cost and technical expertise to 
fabricate and operate. Due to the complex nature and small culture area, microfluidic 
transwell systems have a limited ability to recover cells from culture for downstream 
analysis. Owing to the diversity of designs (single and double layered) microfluidic 
transwell systems vary in their ability for high resolution microscopy during 
experimentation, but many readily facilitate the incorporation of electrodes for TEER 
measurements, enabling them the distinct advantage of performing real time barrier 
monitoring during experimentation in the presence of flow. 
Of the μF-TW BBB devices in the literature, the Wikswo group has produced the 
most comprehensive model to date. Their device can facilitate the co-culture of primary 
human endothelial, pericyte, astrocyte, and neuron cells in the presence of flow. 
Endothelial cells are seeded on a transwell membrane in one compartment, and support 
cells are suspended in a collagen I gel in a separate chamber. This model included more 
cell types in the presence of flow than any other model to date, but it is limited by the 
inclusion of the transwell membrane that prevents direct cell signaling from the support 
cells to the endothelial cells and the presence of a sub-optimal hydrogel system for neural 




2.4.3.2 Microfluidic Lumen Models of the BBB (μF-L) 
As discussed in previous sections, the development of engineered tissue systems 
with a functional and perfusable vasculature component has long been a challenge in the 
field of tissue engineering. In recent years, this problem has been addressed with the 
development of several protocols for the reliable construction of channels within hydrogels 
or microfluidic devices that can be seeded with endothelial cells to form perfusable vessels 
of consistent size and geometry (Section 2.2.4). Of these technologies, only the viscous 
fingering and direct seeding of endothelial cells into preformed PDMS channels have been 
employed in the context of an in vitro BBB lumen device design.   
Using the viscous fingering technique, the Ingber Lab has produced a 3D μF-L 
model of the BBB that is able to incorporate either astrocytes or pericytes along with an 
endothelial lumen in a collagen I hydrogel. This model successfully facilitates the co-
culture of support and endothelial cells in a lumen structure, but remains limited due to the 
inappropriate matrix composition, large lumen diameter (~1mm), and inability to 
simultaneously incorporate multiple support cell types. Additionally, as noted by the 
authors, the device is further limited due to the exuberant amount of media needed to 
maintain constant flow at a rate that will generate physiologically relevant shear stress in 
the lumen [110].  
The Kamm group has also produced a μF-L model of the BBB. Their model utilizes 
micropillars to spatially compartmentalize different cell laden hydrogels around a square 
PDMS channel that is seeded with endothelial cells to form a lumen. Their device facilitates 
the co-culture of primary rat astrocytes, endothelial cells, and neurons in a collagen I 
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hydrogel, but cell contact is limited by the spatial compartmentalization of relevant cells 
types to their separate culture chambers [129]. 
Table 3. Summary of recently published in vitro BBB models. 
 
2.5 Pathophysiology of the BBB 
2.5.1 The Blood Tumor Barrier (BTB) 
While the development of a healthy BBB model is the primary focus of this work, 
because the downstream application is use in the development of novel nanomedicines for 
the treatment of MB, a brief discussion of pathophysiological BBB is necessary. In cases 
of cancer, drug delivery to brain tumors is further limited by the presence of the BTB, a 
secondary barrier that develops from tumor microvessels. Interestingly, BTB physiology 
varies with tumor type and sometimes within tumor subtypes. While some tumor BTBs 
maintain the limited permeability of healthy BBB, typically tumor BTBs are more 
First Author Publication Year Digital Object Identifier (DOI) Model Name Model Type BBB Cell Types Used [origin, p/i] 3D ECM Cell Contact High Throughput Relative Cost Shear Fabrication
Adriani
2017  10.1039/C6LC00638H N/A µF-La
hCMEC/D3 [human,i]; cortical neurons [rat,p]; 
astrocytes [rat,p]
Collagen I Limited
b No Moderate No Simple
Herland
2016 10.1371/journal.pone.0150360 3D BBB Chip µF-L
hBMVEC [human,p],  HBP [human,p ], HA 
[human,p]
Collagen I Limited
c No Moderate Limited
d Moderate
Walter
2016 10.1016/j.snb.2015.07.110 N/A µF-TW
hCMEC/D3 [human,i];  endothelial [rat,p];  
astrocyte [rat,p]; and pericyte [rat,p] 
None No No Moderate Yes
e Moderate
Wang
2016 10.1002/bit.26045 BBBOC µF-TW BMEC [human,hiPSC derived]; atrocytes [rat,p] None No No Moderate Yes Complex
Cho
2015  10.1038/srep15222 N/A µF-L RBE4 [rat,i] Collagen I No No Moderate No Moderate
Kim
2015 10.1063/1.4917508 N/A µF-L b.End3 [mouse,i] Collagen I
f No No Moderate Yes Moderate
Brown
2015 10.1063/1.4934713 NVU µF-TW
hBMVEC [human, p]; HP [human, p];  HA 
[human, p]; neurons [human, hiPSC derived]
Collagen I No No Moderate Yes Complex
Sellgren
2015 10.1063/1.4935594 N/A µF-TW




C µF-TW RBEC [rat, p]; neonatal astrocytes [rat, p] None No No Moderate Yes Moderate
Prabhakarpandian
2014 10.1039/c2lc41208j SyM-BBB µF-TW RBE4 [rat, i] None N/A No Moderate Yes Complex
Urich
2013 doi:10.1038/srep01500 MSC-BBB SP
HBMEC [human, p]; HA [human, p]; HBVP 
[human, p]
None Yes Yes Low No Simple
Griep
2013 10.1007/s10544-012-9699-7 BBB on a Chip µF-TW hCMEC/D3 [human, i] None No No Moderate Yes Moderate
Achyuta
2013 10.1039/C2LC41033H N/A µF-TW
RBE4 [rat, i]; "Nerual Cell Mix" [rat, p: ~4% 
neurons, 95% astrocytes, 1% microglia]





2012 10.1039/c2lc40094d μBBB µF-TW b.End3 [mouse, i]; C8D1A [mouse, i] None No No Moderate Yes Complex
Yeon
2012 10.1007/s10544-012-9680-5 N/A µF-TW HUVEC [human, p] None No No Moderate Yes Moderate
Cucullo
2010 doi.org/10.1038/jcbfm.2010.162 DIV-BBB µF-TW
k HBMEC [human, p]; HA [human, p] None No No Moderate Yes Moderate
Nakagawa 2008 10.1016/j.neuint.2008.12.002 N/A TW
RBEC [rat, p]; cerebral astrocytes [rat, p]; 
cerebral pericytes [rat, p]
None No Yes Low No Simple
a
Authors use an angiogensis chip that could potentially be classified seperately     
b
Contact is limited by pillars compartmentalizing seperate support cell cultures     
c
Only one support cell type at a time was co-cultured with the endothelial 
cells     
d
Flow was not continuously maintained during experimentation due to exuberant media requirement     
e
Authors use perstaltic pumping method to recirculate media     
f
Authors used a bioprinting methodology     
g
polyester membrane 
used in place of polycarbonate membrane for optical clairty     
h
astrocytes were removed from device prior to permeability studies    
 i
Authors state that clamps were needed to add flow or the device leaked     
j
Authors cite contamination issues 
Notes
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permeable than healthy BBB. This increase in permeability, or “leakiness”, in the 
microvessels immediately surrounding tumor sites has been demonstrated to be the result 
of tumor cell mediated tight junction degradation. Existing in vitro BTB models are 
adaptations of established BBB models, and face the same challenges [89, 130].  
2.5.2 The BBB and Medulloblastoma (MB) 
A particularly relevant example of the implications of BBB/BTB physiology on 
tumor prognosis and treatment can be illustrated by examination of the different subtypes 
of MB. MB is the most common pediatric brain tumor, accounting for 10% of all childhood 
cancer fatalities. MB is classified into sub types based on the presence of certain genetic 
mutations and the site of origin of the tumor. Cases associated with mutations to the sonic 
hedgehog (SHH) pathway are more aggressive, carry a poorer prognosis, are more resistant 
to chemotherapy, and are more likely to recur. By comparison, cases that are associated 
with mutations to the WNT/β-catenin signaling pathways tend to be very curable. This 
difference in prognosis and treatability has recently been found to be due to differences in 
how the tumors affect the integrity of the BBB. In WNT subtype MB, the tumor cells 
secrete inhibitors to the WNT signaling pathway that result in disruptions to BBB integrity 
and an increase in barrier permeability. This increase in permeability around the tumor site 
enables more effective delivery of chemotherapeutics and contributes to the disparity in 





Nanomedicine is a broad and diverse field with potential applications in imaging and 
diagnostics, cancer treatment, and the treatment of neurological diseases, and NP platforms 
have been developed for a wide range of diagnostic, therapeutic, and combinatorial 
(“theranostic”) applications. A comprehensive review of the field of nanomedicine as 
whole is outside the scope of this work, but is readily available elsewhere [132-137]. A 
brief overview of synthesis techniques and an overview of the NP types proposed for use 
in our future studies is briefly presented for context. This work is interested in the 
interaction of our NPs with the BBB. Specifically, this and future work aims to determine 
whether functionalization of lipid polymer nanoparticles (LPNP) with apolipoprotein A1 
(ApoA1) will translate to an increase in BBB penetrance, and if this penetrance could be 
visualized and quantified in our MLS-BBB. Furthermore, through such studies, we aim to 
determine if our MLS-BBB will provide more predictive results of ensuing in vivo studies 
(mice) relative to transwell culture. Thus, examples of NP based approaches for increasing 
BBB penetrance are briefly discussed, with focus paid to the influence of physical and 
chemical particle properties on BBB NP interactions. 
2.6.1 Nanoparticle Strategies for Crossing the BBB 
As discussed in Section 2.3.2, nanoparticle platforms have been under active 
investigation as a potential “Trojan Horse” strategy to increase drug delivery to the brain. 
NPs are particularly good candidates for such studies due to their size and tuneable 
physiochemical properties [97, 138, 139]. Effective delivery across biological barriers is 
essential for the successful development of effective nanomedicines, and targeted delivery 
 34 
of drugs across endothelial barriers remains a significant challenge for brain targets, where 
transport is extremely limited by the BBB.  A number of NPs have been studied for their 
potential BBB crossing abilities [140], of which only LPNP and high-density lipoprotein 
(HDL) particles are contextually relevant to this work.  
2.6.1.1 High Density Lipoprotein (HDL) 
 HDL is an endogenous nanoparticle involved in a wide range of functions in the 
body that is a prime candidate for use in drug delivery studies due to its natural 
immunogenicity and ability to be transported by cellular receptors [137]. Apolipoproteins 
like ApoA1 and ApoE from natural HDL can be utilized to make engineered HDL-mimetic 
NPs that maintain bioactivity similar to native HDL [141]. HDL particles are particularly 
well suited as BBB crossing vectors due to their small size (10-25nm), and ability to be 
transported by endogenous transporters [137].  
2.6.1.2 Lipid Polymer Nanoparticles (LPNP) 
LPNPs are composed of a stable polymeric core surrounded by a lipid shell that can 
be functionalized with polyethylene-glycol (PEG) polymers to increase retention in 
circulation by reducing filtration from circulation by the liver and kidneys. LPNPs exhibits 
complementary characteristics of both polymeric NPs and liposomes, enabling their 
superior drug loading and delivery [134].  Many researchers have demonstrated interest in 
further optimizing the potential of LPNPs by hybridizing them with components of 
naturally occurring NPs such as the apolipoproteins associated with HDL [141]. 
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2.6.2 Microfluidic Synthesis of BBB Crossing Nanoparticles  
While nanoparticle composition is of most importance to BBB crossing ability, the 
synthesis methodology also warrants brief discussion as robust synthesis is critical for the 
reliable production of particles with homogenous physiochemical properties, a necessary 
factor in the successful implementation of any nanoparticle system. NP synthesis was 
traditionally conducted via bench top reactions in which nanoprecipitation occurred upon 
agitation of immiscible solvents with magnetic stirring or vortex mixing. While such 
reactions do produce nanoparticles, such production methods often result in particles that 
are inhomogeneous in their size and composition, rendering them poor candidates for 
translation to drug products that must meet industry standards for consistent quality and 
purity. Additionally, bench top synthesis is a batch process that is not conducive to scale 
up to industry relevant production levels that would be necessary for the completion of 
human clinical trials. Thus, benchtop synthesis, while sufficient for preliminary studies of 
nanoparticle formation, is sub-optimal for the synthesis of nanoparticles that aim to 
eventually be translated to effective drug products [142, 143].  
Microfluidic technology has emerged as a robust platform for continuous synthesis 
of nanoparticles with controlled physiochemical properties [144-146]. These 
improvements are largely achieved through the reduction in mixing times that reduces the 
formation of precursor aggregates, a common issue in bench top synthesis. Several 
techniques can be used in microfluidic synthesis of nanoparticles that leverage the ability 
of microfluidics to precisely control flow patterns. In our lab, we employ convection based 
microfluidic mixing via microvortices to synthesize the multifunctional nanoparticles that 
will be evaluated on our MLS-BBB. This synthesis platform creates a controlled, rapid 
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mixing interface between two nanoparticle precursor solutions and enables continuous 




CHAPTER 3. DEVELOPMENT OF MLS-BBB 
3.1 Introduction  
The BBB is the specialized vasculature of the CNS responsible for the regulation of 
transport into the brain from systemic circulation. While the BBB is essential for proper 
neuronal function, it severely restricts the transport of molecules to the brain and poses a 
significant challenge to drug development and delivery [59].  Due to the species variation 
in BBB structure and function that exists between human and animal models, the 
development of a human cell based in vitro model of the BBB is critical for the cost-
effective evaluation of novel drug candidates [100].  Despite a large number of increasingly 
complex in vitro BBB models being presented in the literature [105, 108, 112, 118], no 
model has been adapted for widespread use in preliminary drug studies in place of 
traditional, static, transwell culture systems. This can be attributed to a number of factors 
including a lack of sufficient evidence that demonstrates their increased predictive power 
over simpler models, increased cost of fabrication and operation, lack of ability to perform 
high throughput screening, and increased technical expertise required to establish these 
models [105].  
Several key components contribute to the expression of physiologically relevant 
BBB endothelial cell specializations including exposure to shear stress [147], direct cell-
cell interactions between NVU cell types [82], and a functional lumen structure [104].  
Additionally, recent research indicates that proper ECM composition is necessary for non-
reactive culture of astrocytes [84].  To date no existing in vitro BBB models simultaneously 
include flow and direct cell contact between astrocytes, pericytes, and endothelial cells in 
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a lumen geometry. Furthermore, all currently published microfluidic BBB models that 
include a hydrogel component use a collagen I gel [110, 112, 118], which has been 
demonstrated to induce reactive gliosis in astrocytes [84].  In this work, we address these 
challenges through the development of our novel microfluidic lumen system of the BBB 
(MLS-BBB). Our MLS-BBB is designed to directly co-culture human astrocytes (HA) and 
human brain vascular pericytes (HBVP) with a perfusable, cylindrical lumen of 
immortalized human brain endothelial cells (iHBMEC) contained within a 3D hydrogel 
system tuned to mimic the properties of brain ECM.  
3.2 Materials and Methods 
3.2.1 Hydrogel Optimization for Appropriate Astrocyte Culture 
High concentration collagen I (Corning) and growth factor reduced, phenol red free, 
Matrigel (Corning) were studied individually, and in combination with brain relevant ECM 
proteins (Tenascin C, TC; hyaluronic acid HY) to determine the best 3D culture conditions 
for human astrocytes (P2-3, Sciencell). Matrigel was selected for use due to similarities 
between its composition (~30% collagen IV, ~60% laminin, ~8 entactin) and in vivo brain 
ECM. Collagen I was included for comparison to commonly used methodologies in 
existing in vitro BBB devices.  
HAs were seeded in hydrogels at a concentration of 3E5 cells/mL and cultured for 
1-7 days before being imaged or recovered for use in HT-qPCR analysis of reactive gliosis 
marker expression (Figure 4). Six 3D culture conditions were tested and compared to a 2D 
culture control. Composition of 3D ECM conditions tested were as follows: Collagen I 
(6mg/mL), Matrigel (6mg/mL), Collagen I (6mg/mL) + Hyaluronic Acid (3mg/mL) + 
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Matrigel (3mg/mL), Matrigel (6mg/mL) + Hyaluronic Acid 3mg/mL) + Tenascin C 
(5ug/mL), Matrigel (6 mg/mL) + Hyaluronic Acid (3mg/mL) and Matrigel (6mg/mL) + 
Tenascin C (5ug/mL). Cells were harvested after either one day or one week of culture for 
qPCR analysis of the expression of 13 genes associated with the presentation of a reactive 
gliosis state in astrocytes.  
 
Figure 4. Schematic of workflow for gel tuning study. Human astrocytes were 
suspended in hydrogel precursor solutions and injected into PDMS culture wells bonded 
to glass coverslips.  
3.2.2 qPCR Analysis 
Markers of reactive gliosis were selected via review of relevant literature [72, 85-
88, 148-152]. Sequences for each gene target were obtained from the NCBI nucleotide 
database and primers were developed for each target using Primer3Plus software and 
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BLAT tools. Primers were ordered from Eurofins Genomics and suspended in TE buffer 
(TekNova) at a concentration of 100μM. RNA was extracted from 3D cultures via Quiagen 
RNeasy micro kits. In samples obtained from 3D culture, 40µL of proteinase K was added 
to lysates and an additional incubation at 55ºC was added before removal of genomic DNA 
in order to remove residual matrix proteins from the sample as indicated by manufacturer.  
Hydrogels containing collagen I were further processed in a Qiashredder column to remove 
residual ECM proteins from the sample. A detailed discussion of RNA extraction 
methodologies and justification for differences in sample handling can be found in Section 
6.3.  Extracted RNA purity was determined from the 260/280 ratio for all samples. Samples 
were analyzed for degradation by obtaining a RNA integrity number (RIN) from 
bioanalyzer data. RIN scores of 6+ are considered of sufficient quality for use in HT-qPCR, 
and tested samples ranged in quality from 6.5-9.9. RNA concentration was measured via 
spectrophotometry (Take3, BioTek plate reader) and diluted to a homogenous 
concentration across all samples with RNase free water before conversion to cDNA for 
PCR. Conversion to cDNA was accomplished via high throughout reverse transcription kit 
(ThermoFischer) in a standard thermocycler via manufacturer’s instructions. High 
throughput qPCR was carried out in the Georgia Tech Genomics Core via the Biomark 
Fluidigm System with Evagreen detection. Three biological replicates of each sample were 
included for analysis. Raw cycle threshold (Ct) values were normalized to the geometric 
mean of 3 housekeeping genes to obtain ΔCt values. ΔΔCt were obtained via normalization 
to 2D cultured astrocytes to facilitate comparison across 3D culture conditions and fold 
change values were obtained by taking 2- ΔΔCt . 
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3.2.3 Device Component Preparation and Device Assembly 
3.2.3.1 PDMS Component Preparation  
Polydimethylsiloxane (PDMS) was used for the fabrication of culture housings due 
to its optical properties [153] and permeability to gaseous oxygen exchange [154, 155]. All 
PDMS devices used were cast via traditional soft lithography on 3D printed molds (Objet 
Eden printer, Georgia Tech Invention Studio).  PDMS base was combined with curing 
agent in a ten to one ratio before being thoroughly mixed and poured into molds. Molds 
were degassed for 20 minutes at room temperature to remove bubbles before being cured 
for at least 1 hour at 80ºC. After cooling to room temperature, PDMS slabs with housing, 
element, or reservoir features were cut out of molds and inlets and outlets were punched 
with a 1mm biopsy punch. Reservoirs were punched with 8mm biopsy punches to increase 
the volume available for flushing and to accommodate reservoir expanders for 
administering shear to devices.  
3.2.3.2 Sacrificial Element Injection Mold Assembly 
Cylindrical sacrificial element injection molds were made by reversibly bonding 
two semi-circular PDMS molds as depicted in Figure 5A. Two element molds were used 
to cast each batch of 150 µm elements. Inlets and outlets were punched in the alignment 
bulbs of one mold to allow for infusion of the gelatin solution after injection mold 
assembly. Inlets and outlets were punched with a ~30 degree angle offset in element molds 
to prevent the entrapment of bubbles in the alignment bulbs during injection molding. Both 
sides of the injection mold were cleaned three times with tape and one side of the mold 
was then plasma cleaned for 2 minutes before being aligned with its complimentary (un-
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plasma cleaned) mold under a stereoscopic microscope. Assembled injection molds were 
clamped between aluminium slabs and heated to 80ºC for at least one hour before 
proceeding with the element casting process.  
3.2.3.3 Sacrificial Element Casting 
Elements were cast using previously validated methodologies depicted in Figure 
5A [42]. Briefly, Pluronic F127 (PF127, 6% in PBS) was injected into each injection mold 
to prevent the attachment of gelatin elements to the PDMS. PF127 was allowed to adsorb 
to the PDMS for one hour and was aspirated out via vacuum suction immediately before 
gelatin injection. A solution of 10% gelatin (from porcine skin, in PBS) was vortexed and 
heated to 80ºC for ten minutes prior to injection into molds with a 1mL syringe and 22-
gauge lure lock needle. In order to prevent gelation before injection was complete, the 
syringe and needle were also heated to 80ºC. In some cases, the gelatin solution was doped 
with GFP to allow for fluorescent imaging of sacrificial elements within devices. Sacrificial 
elements were placed in humid chambers and cured for at least 6 hours at 4ºC before use.  
3.2.3.4 MLS-BBB Device Assembly 
Double sided silicone tape (50µm thick, 3M) was laser cut (Universal Laser System 
VLS3.50) in designs matching housing and reservoir geometries and included in device 
assembly to reduce leaks occurring from incomplete plasma bonding caused by the surface 
roughness of PDMS parts cast from 3D printed molds.  After fabrication of all individual 
components, device housings were assembled together as depicted in Figure 5.  
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Briefly, the bottom of the reservoirs and the top of the housings were cleaned three 
times each with scotch tape to remove dust before the application of silicone tape to the 
bottom of the reservoir. Housings and reservoirs were then plasma cleaned for 2 minutes 
on high and bonded together. Assembled housings were clamped between aluminium slabs 
and heated at 80ºC for at least 30 minutes before subsequent cleaning and sterilization 
(70% ethanol, UV sterilization) for use in cell culture.  
Assembled housings were prepared for assembly into complete devices by cleaning 
the culture area of the housing with 70% ethanol, drying with a pressurized nitrogen gun, 
and cleaning three times with tape. Glass slides were cut to appropriate sizes with glass 
scorers and slides were subsequently cleaned with 70% ethanol and dried. Silicone tape for 
improved attachment of housings to glass was added after the glass was cleaned three times 
with tape. Prepared housings and glass slides were plasma cleaned for 2 minutes while a 
sacrificial element was carefully recovered from an injection mold with tweezers and 
prepared for placement. Sacrificial elements were carefully aligned within the culture 
chamber of the housing and were sealed in place in the device by careful alignment of the 
silicon tape coated glass slide to the housing. This design and assembly facilitates the 
complete encapsulation of the sacrificial element by the cell laden hydrogel while 
preserving access to eventual inlets and outlets for cell seeding and media perfusion.  
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Figure 5. Sacrificial element formation and encapsulation in device. (A) Sacrificial 
element injection molds were fabricated by reversibly binding two PDMS slabs with 
semicircular features. (B) Explosion view of all device components (C) Schematic of the 
assembly process of device components.  
3.2.4 Channel Formation and Cell Seeding 
3.2.4.1 Channel Formation 
After sealing elements in devices, PDL (1mg/mL, Advanced Biomatrix) was 
injected around the element to prevent delamination of the hydrogel from housing walls. 
Devices containing elements in PDL were incubated for at least one hour at room 
temperature, in a humid chamber. Devices were kept in clear petri dished during this 
incubation and placed under UV for additional sterilization. After sterilization, 1mm plugs 
were placed in the inside set of inlet/outlets to prevent the hydrogel from blocking them 
and preventing cell seeding and media perfusion.  Reservoirs were filled with PBS prior to 
plug placement and hydrogel seeding to prevent bubbles from entering the culture chamber. 
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Cell laden or plain gel was then slowly injected around element via a 20uL injection. After 
gelation of hydrogel for 15min at room temperature, media was added to the reservoirs and 
the plugs were carefully removed from the inlet and outlet. Sacrificial elements were then 
melted by incubation at 37ºC for at least 15 minutes and exhaustively flushed via the 
periodic exchange of reservoir media. In some cases, sacrificial elements were doped with 
GFP during casting so that complete element clearance from the device could be confirmed 
before attempting cell seeding. 
3.2.4.2 Cell Seeding 
Human astrocytes (HA, Sciencell, P3) were included in the hydrogel at a 
concentration of 3E5 cells/device (~1.5cells/mL in hydrogel solution, 20µl/device). Human 
brain vascular pericytes (HBVP, Sciencell, P2) were added to the cleared channel in a 
single injection. Before injection, reservoirs were filled with media and inlet/outlet plugs 
were placed in the inlet and outlet used for hydrogel seeding to prevent HBVP cells from 
accumulating outside of the channel space. A 10µL injection of a 1.5E7 cell/mL solution 
was used for every chip. HBVP cells were allowed to adhere for 30 min before media 
exchange from reservoirs. HBVP presence in channels was confirmed via observation with 
phase contrast microscopy and cells were incubated for at least 12 hours before iHBMEC 
seeding. iHBMEC cells (P2-4) were injected into the channel space in 2 10µL injections 
of 3E7 cell/mL solutions. Chips were inverted after the first injection to encourage 
iHBMEC cell attachment to all channel walls. Inverted chips were incubated at 37ºC and 
5% CO2 for 30 minutes before receiving the 2nd HBMEC injection. 30 minutes after the 
second iHBMEC injection, reservoirs were filled with media and devices were incubated 
overnight to allow for iHBMEC cell attachment and lumen establishment. Lumen 
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formation and constriction by endothelial cells was observable as soon as 5 hours after 
iHBMEC addition to channels. After at least 12 hours of iHBMEC static culture in the 
channels, devices were modified to facilitate exposure to physiologically relevant shear 
rates. 
 
Figure 6. Channel formation and cell seeding in assembled device. (A) Schematic of 
assembled device with critical features labeled. (B) Sacrificial elements were suspended in 
empty housings with the alignment bulbs placed at the eventual inlet and outlets. PDL was 
injected and allowed to adsorb to the surface of the housing and element for one hour under 
UV sterilization before careful injection of the HA laden hydrogel precursor around the 
element. Devices were cured at room temperature for 15 minutes before being placed under 
incubation (37ºC, 5% CO2) and flushed exhaustively with astrocyte media overnight to 
dissolve the sacrificial element and produce a channel. (C) HBVP and iHBMEC cells were 
added to culture via infusion into the channel space. HBVPs were seeded a single time and 
allowed to adhere for 12 hours before the addition of iHBMEC cells in two doses. After 
the first injection of iHBMECs, devices were flipped over and incubated for 30 minutes to 
allow iHBMEC cells to cover all sides of the channel space. Devices were then placed right 
side up and injected with iHBMEC cells a second time. Devices were incubated for at least 





3.2.5 Administration of Shear via PF-GDF 
  After at least 12 hours of iHBMEC static culture in the channels, devices were 
modified to facilitate exposure to physiologically relevant shear rates. Autoclaved 1mL 
pipette tips (base diameter = 8mm = reservoir diameter) were inverted and carefully placed 
into the inlet reservoir to create a reservoir expander capable of accommodating the ΔV 
(547µL) necessary to generate a wall shear stress of ~ 4 dynes/cm2. All reservoirs were 
then completely evacuated of media and programmable syringe pumps were used to fill the 
inlet reservoir with 547µL of media while the outlet reservoir was being help empty via 
vacuum aspiration. One minute later, infusion to the inlet reservoir was started at 
8.93uL/min. The ΔV between the reservoirs was maintained over time via the continuous 
infusion of media and continuous vacuum aspiration of outlet reservoirs. Holes were drilled 
in the lids of the petri dish plates to accommodate the tubing for the inlets and outlets and 
the protruding reservoir expanders to minimize exposure of devices to circulating air in 
order to protect against contamination.  
Devices were originally designed with the intention of submerging them in media 
and using programmable syringe pumps to withdraw media at a set flow rate as this method 
has proved successful for the generation of shear over endothelial monolayers in 
microfluidic transwell cultures [156]. However, due to the sensitivity of our hydrogel 
systems to mechanical fluctuations in pump activity, this method was not able to be used 
with our devices. As an alternative, we modified our design to include reservoirs atop the 
inlet and outlet of our device to enable the generation of flow from the pressure gradient 
generated by volume differences in the two reservoirs. This method of gravity driven flow 
is common in the field [58] and was sufficient for flushing, seeding, and feeding devices 
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but could not readily enable the generation of large enough volume gradients to drive flow 
at the rates needed to generate physiologically relevant shear rates. Additionally, this 
method requires the operator to repeatedly exchange media in the reservoirs to maintain 
the gradient necessary for the generation of flow. To eliminate these issues, we added 
separate inlets to our reservoirs that enabled media to be infused from the bottom, outer 
edge of the reservoirs. This enabled the reservoirs to serve as a bubble trap and provided 
insulation from disturbances generated from the syringe pump. To maintain a steady flow 
rate over time, vacuum aspiration lines were connected to the outlet reservoirs and vacuum 
aspiration was continually applied. This enabled the infusion pumps to be set to a flow rate 
that would maintain the volume difference between the two reservoirs necessary for the 
generation of a stable flow rate. In test cases where shear stress was necessary, reservoir 
expanders were added to the inlets of the device to accommodate larger volumes and thus 




Figure 7. Administration of flow via PF-GDF. (A) Continual infusion and withdrawal 
from reservoir inlets and outlets enables the generation of a steady flow rate over time 
while also creating a bubble trap in the inlet reservoir. (B) Equations needed to relate wall 
shear stress to volume difference between reservoirs. Shear stress is directly related to flow 
rate and fluid viscosity and is inversely related to channel diameter (Eqns. 1-2). In this case, 
the pressure drop through the channel is equivalent to the pressure drop due to gravity 
between the two reservoirs, so the expressions for pressure drop from the Hagen Poiseuille 
and Bernoulli equations can be equated (Eqn. 3) and used to define a relationship between 
WSS and ΔH (Eqn. 4) which can in turn be used to define a relationship between ΔV and 
WSS (Eqn. 5). (C) Left: Table detailing the height/volume difference between reservoirs 
needed to drive flow at physiologically relevant rates. Middle: Schematic showing how 
reservoir expanders must be added when the volume difference needed exceeds the max 
fill volume of the reservoirs (500μL). Right: Image of MLS-BBB devices undergoing 
constant media infusion to generate a wall shear stress of 4 dynes/cm2 
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3.2.6 Histology and Imaging 
Traditional immunostaining techniques [71, 157] were used to examine expression 
of tight junctions (ZO-1) between neighboring endothelial cells. Distinct cell markers 
(CD31, αSMA, GFAP) were used to examine the spatial distribution and interaction of the 
NVU cell types. Confocal microscopy was used to acquire 3D reconstructions of cell 
models (Zeiss 700a). Images were processed with Volocity 3D Visualization software. 
3.2.7 Statistics 
Detailed discussion of data handling and statistical analysis can be found in Section 
6.5. Briefly, data are presented are mean values ± standard error of the mean (S.E.M.) for 
N=3 replicates, unless otherwise noted. All statistical analysis was performed in GraphPad 
Prism software.  For comparisons of the expression profiles of two groups, a Wilcoxon 
matched pairs signed rank test was used. For comparisons of the expression profiles of 
more than two groups, a Friedmans’ test was used in conjunction with a Dunn’s post-test 
to correct for multiple comparisons. When applicable, p values were adjusted for multiple 
comparisons.  p < 0.05 was considered statistically significant.  
3.3 Results and Discussion 
3.3.1 Hydrogel Tuning Decreases the Expression of Reactive Gliosis Markers in Human 
Astrocytes 
Reactive gliosis of astrocytes has been implicated in many disease states including 
AD, stroke, and neuro inflammation [85, 86]. Due to the interdependent relationship of the 
cell types of the NVU, it is likely that improper astrocyte culture conditions could create a 
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pathophysiological rather than a physiological model of the BBB, which would likely yield 
non-predictive results if used for preliminary drug studies. To address this potential pitfall, 
we tailored our hydrogel system to facilitate the appropriate culture of astrocytes via the 
inclusion of brain relevant extracellular matrix proteins. We tested various combinations 
of collagen I, Matrigel (Mat), hyaluronic acid (Hy), and tenascin C (TC) [158] to determine 
the most appropriate culture conditions via the evaluation of the expression of several 
markers [88] indicative of the presentation of a reactive gliosis state in astrocytes. Markers 
assessed include markers of astrocytic scar phenotype (NCAM, EGFR), intermediate 
filament proteins (BFGF, NES, GFAP, VIM), protective activation (SYNM, CLCF1, LIF), 
damaging activation (IL6, C1R, C1S) and reactive gliosis (LCN2, SERPINA3N, CD109). 
Expression levels were evaluated in astrocytes isolated from each culture condition to 
determine the best hydrogel system for physiological astrocyte culture. Additionally, we 
verified the presence and consistent expression of two markers commonly used for labeling 
of astrocytes (AQP4, ALDH1L1) as a control.  
  The fold change in marker expression relative to 2D was obtained for each hydrogel 
condition via normalization of raw qPCR data to the expression of 3 housekeeping genes 
and to 2D culture results. The resulting expression profiles were compared to determine 
which conditions provided the lowest relative expression of markers after one day and one 
week of culture. Our results support existing literature evidence that 3D culture results in 
a less reactive state than 2D culture [159]. While no single hydrogel condition performed 
best for every marker assessed, our results indicate that MatHy and MatTC each provide a 
significant reduction in marker expression when compared to collagen I gels after one week 
of culture. This result is consistent with literature evidence suggesting that TC can 
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contribute to the recovery of non-reactive state in the 2D culture of astrocytes [158], and 
makes logical sense as Matrigel is primarily composed of BBB relevant ECM proteins 
(~30% collagen IV, 60% laminin, and 8% entactin). Furthermore, comparison of 
expression profiles over time (one day vs. one week) indicates that both MatHy and MatTC 
hydrogels facilitate a significant reduction in marker expression over time, further 
indicating their ability to facilitate the recovery of a quiescent state. Based on these results, 
MatTC hydrogels were selected for use in our MLS-BBB device.  
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Figure 8. MatTC hydrogels exhibit lowest relative expression of reactive markers. 
Radar plots depicting the expression of markers for reactive gliosis relative to 2D culture 
after (A) 1 day and (B) one week of culture in various 3D hydrogel compositions. No 
significant differences in expression profiles were observed across the hydrogel 
compositions tested after one day of culture (C) Only MatHy and MatTC hydrogels have 
significantly different expression profiles than collagen I after one week of culture. (E-J) 
Before and after plots showing the change in expression profile over time for each hydrogel 
condition assessed. Only (I) MatHy and (J) MatTC demonstrate a significant reduction in 
marker expression over time. Data depicted as mean +/- SEM for an N=3 for all samples. 
*p<0.05, **p<0.01, n.s. – not significant.  
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 Microscopic examination of astrocytes further validated the suitability of MatTC 
for appropriate 3D culture. Inspection reveals marked morphological differences from 2D 
culture including a reduction in cell body size and an increase in the number, length, and 
bifurcations of astrocyte projections (Figure 9) 
 
Figure 9. Observable morphological differences between 2D and 3D culture. HAs 
cultured in MatTC hydrogels exhibit more appropriate morphology indicated by the 
reduction in cell body size and an increase in the number, length and bifurcations of 
astrocytic projections (red arrows).  
 
3.3.2 Sacrificial Element Methodology Enables the Formation of Perfusable iHBMEC 
Lumens 
In this work, we adapted a sacrificial element method to craft perfusable channels 
within cell laden hydrogel systems as previously described [42]. Encapsulation of a 
preformed sacrificial gelatin element within our PDMS device housing enables the full 
encapsulation of the sacrificial element and the subsequent formation of a channel. 
However, direct infusion or withdrawal of media into these hydrogel channels often 
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resulted in the destruction of the formed channel due to the low mechanical strength of the 
hydrogel systems used and the propagation of mechanical disturbances from the syringe 
pump. Thus, reservoirs were added to enable the generation of flow via less disruptive 
gravity driven flow. In order to maintain a constant flow rate over time, generation of flow 
via gravity requires the constant (~12hour) refreshment of media in the reservoirs to 
prevent the cessation of flow due to reservoir equilibration. As this can become quite time 
consuming when the simultaneous culture of several MLS-BBBs is desired, we chose to 
maintain the volume difference between the inlet and outlet reservoirs via the constant 
infusion into the inlet reservoir from a programmable syringe pump and the constant 
aspiration of media from the outlet reservoir. Using this “pump-facilitated gravity driven 
flow” (PF-GDF) method, we were able to successfully culture as many as 70 MLS-BBB 
chips simultaneously. Through the addition of inverted pipette tips, we were also able to 
modify our devices to accommodate the volume difference necessary to drive flow at a rate 
that produces a wall shear stress similar to in vivo conditions (4 dynes/cm2) [120]. 
 
Figure 10. Sacrificial element methodology enables the formation of endothelial 
lumens within MLS-BBB device.  (Left) GRP doped sacrificial element surrounded by 
Cell Tracker Deep Red labeled astrocytes (Right) Bright field images of three MLS-BBB 
devices with cutout to higher magnification phase contrast image. Lumen location in each 
device indicated by white arrows.   
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3.3.3 MLS-BBB Device Enables Culture of NVU Cell Types in Lumen Geometry 
To assess the formation of BBB lumens within our MLS-BBB, our model was then 
stained for distinct cell markers to enable visualization of cell morphology and spatial 
arrangement of the relevant cell types of the NVU. Histological staining for ZO-1 verified 
the formation and connection of iHBMEC cells into a monolayer, GFAP staining revealed 
branched astrocytes and an interconnected system of astrocytic processes spanning the 
length of the lumen, and staining for αSMA enabled the visualization of pericyte 
localization and coverage of the endothelial lumen. 
 
Figure 11. Lumen formation in MLS-BBB. (A) Schematic illustration of MLS-BBB 
device. Red dashed box indicates culture area (B) Extended focus image of iHBMEC 
(green, ZO-1) lumen lined by HBVP (red, αSMA) cells and wrapped with HA (white, 
GFAP) endfoot projections in MLS-BBB device. Cell nuclei visualized via DAPI staining 
(blue). (C) Astrocytes surrounding iHBMEC lumen form interconnected nets (D) ROI 
showing astrocyte contact with iHBMEC lumen. Image courtesy of S. Ahn. (E) 3D 
renderings of iHBMEC (green) HBVP (red) co-culture illustrating the localization and 
extent of HBVP coverage over iHBMEC lumen. (F) GFP doped sacrificial element 
suspended in TRITC doped Matrigel confirming rounded shape of injection molded 
elements used for channel formation (G) XZ projection of an MLS-BBB lumen confirming 
that this rounded channel shape is maintained in culture. 
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3.4 Opportunities for Improvement 
While this work was successful in the creation of a MLS-BBB, there are several areas 
for potential improvement to the device design and workflow that warrant discussion. The 
sections that follow discuss areas for improvement identified by the issues encountered 
throughout experimentation with our MLS-BBB system along with suggested directions 
for improvement.  
3.4.1 Limitations of 3D Printed Substrates for Soft Lithography 
The current MLS-BBB device is limited by the dependency on 3D printing to 
generate cylindrical sacrificial element molds. While 3D printing technology is capable of 
printing reliable features at sizes down to the nanometer scale, the printers that can 
accomplish this are often not designed for printing of large surface areas. The Objet Eden 
System used could print features in the size necessary for our molds (~100-500µm) at a 
reasonable price point, but the minimum resolution of the printer (10µm) was high enough 
to cause variability on the surface of the mold. This significant and variable (from mold to 
mold), surface roughness was sufficiently high to produce leaks in devices unless PDMS 
pieces were used in conjunction with double sided silicone tape. The addition of silicon 
tape between housings and reservoirs and between housings and glass coverslips was 
sufficient to reduce device leaks; however, silicon tape could not be reliably used in the 
protocol for the formation of sacrificial elements due to difficulties with alignment. Thus, 
sacrificial element injection molds often leaked and the casting process was inefficient. On 
average, 50% if elements cast were usable for experimentation.  
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In addition, over the course of experimentation we observed that the Objet Eden 
3D printed molds are not well suited for continuous use in the casting and curing of PDMS 
due to their tendency to warp after extended exposure to heat.  On average, molds lasted 
for 25 castings before replacements became necessary.  For future studies, we recommend 
either the use of a 3D printer capable of producing smoother surfaces in finished parts, 
post-treatment of 3D printed parts to smoothen surfaces, or the adaptation of a traditional  
photolithography based approach that utilizes silicon wafers for the creation of sacrificial 
element master molds.  
3.4.2 Sterility  
3.4.2.1 Mitigation of Contamination Hazards 
The current workflow could be improved with modifications that would enable 
more steps to be carried out in a sterile field. Although device contamination was only 
observed in 1 out of 30+ batches of devices, the risk of contamination is quite high due to 
the number of process steps that must be completed outside of a sterile field (plasma 
cleaning, element placement in devices, etc.). Suggestions to reduce contamination hazard 
include: placing a stereoscopic microscope in a laminar flow hood for use during alignment 
and seeding steps, reduction in distance between plasma cleaner and laminar flow hood, 
and the acquisition of sterile containers of sufficient height to accommodate the full height 




3.4.2.2 Re-sterilization and Re-use of Device Components 
Assembled housings, while intended for single use, were tested for their ability to 
be re-used successfully due to a looming PDMS shortage facing the Georgia Tech 
community in May of 2017. Removal of silicon tape with scotch tape, sterilization with 
70% ethanol, and subsequent autoclaving proved efficient at preparing used housings for 
re-use as demonstrated by microscopic inspection of device features. Preliminary tests 
conducted with such devices yielded indistinguishable results from newly assembled 
housings, indicating that in some cases previously used, assembled housings could be re-
used if properly sterilized.    
3.4.3 Modification to High Throughput Design 
This workflow is not currently conducive to scale up. The ability to produce 
massively paralleled and repeatedly identical devices is necessary if the are to be used for 
pharmaceutical development. Throughout the course of experimentation with these 
devices, a maximum of 70 devices were cultured simultaneously. While possible, this was 
extremely labor intensive, requiring the constant (18 hour/day) attention and care of the 
operator and an assistant. The necessity of individual element placement and injection into 
each chip greatly limits the speed with which devices can be made. A system in which 
replicate devices could be assembled and injected as a unit would be a significant 
improvement to the current workflow.  Additionally, a system in which tubing could be 
easily connected to a number of devices in parallel would greatly expedite the setup of 
parallel experiments.  
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3.4.4 Material Limitations 
3.4.4.1 Necessary Cell Lines 
In order to ensure that cells form stable lumens, extremely high concentrations of 
brain endothelial cells must be injected into the channel. Primary HBMECs are expensive 
(~$700/vial) and are only guaranteed by most vendors for four population doublings (Note: 
this is distinctly less than 4 passages). Additionally, primary HBMEC cells are in short 
supply due to their sourcing, and were at times not available when needed. Due to limited 
sources of primary cells, cells from multiple vendors were ordered over the course of 
device design and troubleshooting, and we noted significant differences in cell quality and 
expansion potential from these different vendors. Based on our experience, we recommend 
Sciencell for the purchase of primary HBMECs, as they provided cells of the most robust 
and consistent quality. Due to this limitation, the majority of our experiments were carried 
out with immortalized HBMEC cells (iHBMEC, DV Biologics).  
3.4.4.2 Media Requirements  
This workflow also necessitates the use of a significant amount of media during the 
course of experimentation. For a shear stress of 4 dynes/cm2, a flow rate of 8.93µL per 
minute (~13mL per day per device) is needed, which could quickly become unsustainable. 
To mitigate this waste, our MLS-BBB was only cultured in the presence of shear for 24 
hours after the establishment of an HBMEC lumen in the device before being harvested for 
analysis. Subsequent iterations of our MLS-BBB would benefit from a design modification 
that allows for partial media recirculation or from a reduction in lumen diameter to decrease 
the flow rate needed per chip to generate physiologically relevant shear rates.  
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3.4.5 Post Processing of Samples 
Our device assembly itself readily facilitates the recovery of lumens from the 
devices due to the presence of the silicone tape between the housing and the glass slide. 
Housings can be carefully peeled so that hydrogel constructs are left in place on the glass 
slide (failure rate of recovery <15%). These constructs can then be fixed and stained for 
microscopy using standard methods. However, we did note significant degradation of our 
hydrogel system (MatTC) throughout the course of fixation and staining. This challenge 
result in a loss of information that could be gathered if constructs could be imaged before 
degradation of the structure. This can be partially mitigated by fixing with 2% PFA in place 
of 4% PFA, but the multiple wash steps necessary for staining with good signal to noise 
ratio still remove a significant portion of the astrocyte containing hydrogel from the lumen 
structure before it can be imaged. This could be potentially mitigated via hydrogel 
stabilization with glutaraldehyde treatment prior to fixation. Alternatively, live cell staining 
techniques could be used in conjunction with antibodies for extracellularly located, cell 
type specific proteins.  
3.5 Conclusion 
Our MLS-BBB constitutes a significant contribution to the fields of OOAC 
development and tissue engineering in that we successfully produced the first in vitro BBB 
model system capable of simultaneous incorporation of a tubular endothelial lumen, non-
reactive astrocytes, and pericytes in the presence of physiologically relevant flow rates. We 
validated the appropriate arrangement and interaction of the cells in our model via 
fluorescent microscopy of distinct cell markers and verified the presence of tight junctions 
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between endothelial cells via ZO-1 staining. We have also highlighted and discussed 
potential improvements for alteration in subsequent iterations of this device for 
consideration.  
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CHAPTER 4. HT-QPCR CHARACTERIZATION OF MLS-BBB 
4.1 Introduction 
One of the challenges facing wide spread implementation of OOAC model systems 
is the lack of evidence demonstrating their increased predictive power over simpler models. 
In the context of the BBB, predictivity depends on the appropriate expression of a number 
of BBB specific endothelial cell specializations such as increased expression of junctional 
proteins between neighboring endothelial cells (ZO-1), expression of drug resistant 
proteins and active drug efflux pumps (Pgp), and the appropriate expression of relevant 
surface receptors (GLUT-1) [100]. A cursory review of the literature yields hundreds of 
targets that are characteristically or differentially expressed in endothelial cells of the BBB 
[72, 148, 150-152]. Despite this, novel OOAC BBB models presented in the literature are 
largely characterized via histological verification of the expression of 1-5 relevant proteins 
in conjunction with TEER or permeability assays before proceeding to demonstrations of 
utility [108]. While these metrics do provide some insight as to the relevant specialization 
of the endothelial cells, they are by no means comprehensive. Additionally, such narrow 
analyses seem to be predicated on the assumption that the relative expression of a single 
endothelial cell specialization (such as ZO-1 or Pgp) could somehow be indicative of 
appropriate expression of all relevant specializations.  
In order to determine whether our MLS-BBB provides a significant increase in the 
expression of BBB relevant endothelial cell specializations, we characterized our model 
via high throughput qPCR (HT-qPCR, Biomark Fluidigm System) analysis for the 
expression levels of 81 genes demonstrated in the literature to be differentially or 
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characteristically expressed in brain endothelial cells. By comparing the fold change in 
expression of each target relative to static culture of iHBMECs, we can begin to quantify 
the relative strengths of our model and identify areas of weakness for improvement in 
future iterations. We further expanded this study to evaluate whether our culture in our 
MLS-BBB facilitates the expression of more BBB relevant specializations than simpler 
models by comparing the expression profiles of endothelial cells extracted from our MLS-
BBB and endothelial cells extracted from transwell and spheroid models. We further 
validated our MLS-BBB by assessing our model’s ability to dynamically respond to 
stimulation by TNFα. Finally, we studied how ECM composition impacts BBB cell 
specialization by varying the composition of the hydrogel system used in our model. 
 
Figure 12. Schematic of experimental workflow for HT-qPCR experiments. iHBMEC, 
HBVP, and HA cells were grown to confluence in T300 flasks before trypsinization and 
seeding into various in vitro BBB models. After 5 days of culture, all model cultures were 
terminated and iHBMEC cells were recovered via FACS. RNA was isolated and converted 
to cDNA for use in HT-qPCR analysis for the expression of BBB relevant endothelial cell 
specialization. 
4.2 Materials and Methods 
4.2.1 Transwell Culture 
Polyester transwell inserts (pore size 0.4um, Corning) were submerged in a 0.1% 
gelatin solution for at least one hour and rinsed with PBS before cell seeding. The inserts 
were inverted onto a petri dish and HBVPs were seeded on the bottom side of the inserts 
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while HAs were seeded in the wells. Cells were allowed to adhere for two hours before the 
HBVP laden transwell inserts were inverted into the HA wells. iHBMECs were then seeded 
onto the upper side of the transwell inserts. All cell types were seeded at a concentration 
of 1E5 cells/cm2. Cell growth was monitored via fluorescent microscopy and monolayer 
formation and integrity was validated via TEER measurements. 
 
Figure 13. Schematic of tri-culture transwell (TWEAP) model establishment and 
model validation via TEER. TEER measurements of mono-, co-, and tri-culture 
conditions reflect previously reported data that barrier establishment and integrity is highly 
dependent on the presence of astrocyte cells.   
4.2.2 Spheroid Culture 
Round bottom, 96 well, ultra-low attachment culture plates were used to generate 
spheroids. Individual cell suspensions of iHBMEC, HA, and HBVP cells were prepared at 
a concentration of 5E4 cells/mL in cell specific media and seeded in a ratio of 2:1:1, 
iHBMEC:HA:HBVP. Cell suspensions were distributed into ultra-low attachment plates 
(200µL/well) via a multichannel pipette to reduce variation.  
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Figure 14.  Schematic of tri-culture spheroid (SPEAP) seeding protocol and 3D 
rendering confocal image of a SPEAP. Image: HBMEC (green), HBVP (red), NHA 
(blue) cells confirms the formation and appropriate arrangement of relevant cell types. 
Scale bar 100µm. 
4.2.3 MLS-BBB Culture 
  MLS-BBB Culture was conducted as outlined in Section 3.2.4 for mono- co- and 
tri- culture experiments. In cases where administration of TNFα was necessary, MLS-BBB 
models were cultured with TNFα supplemented media (40ng/mL) during the 24 hours 
following administration of shear and preceding harvesting. Additional hydrogel 
compositions were included for analysis including plain collagen, plain Matrigel (no 
tenascin C), and a CnIMatHy combination hydrogel. Hydrogel compositions were kept 
consistent with those used in Section 3.2.1. 
4.2.4 Fluorescent Activated Cell Sorting 
In order to collect pure iHBMEC samples from co-culture experiments for qPCR 
analysis, iHBMEC cells were stained with a conjugated antibody for a distinct endothelial 
cell marker (CD31) after termination of culture. Where applicable, cell constructs were 
dissociated from tri-culture models with 5% trypsin solution (2D culture) or 1:1 mixture of 
trypsin and Corning Dispace (3D culture). Cell suspensions were centrifuged and re-
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suspended in FACS buffer to remove any residual ECM proteins before being filtered thru 
a 40uM cell strainer and used for FACS to isolate endothelial cells from astrocytes and 
pericytes. FACS protocols were built via standard methods, and controls for dyed and 
undyed cells were included in each sorting session to reduce capture of non-iHBMEC cells. 
Cells were sorted directly into lysis buffer stabilized with RNase inhibitors to prevent the 
degradation of genetic material prior to analysis. Careful attention was payed to ensure that 
the volume of the sorted cell suspension being added to the lysis buffer was not enough to 
dilute its potency (indicated as critical by kit manufacturer. A 3:1 or greater ratio was 
maintained between volumes). 
4.2.5 qPCR Analysis 
  Targets for BBB relevant endothelial specializations were selected via review of 
relevant literature [72, 148-152]. Sequences for each target were obtained from the NCBI 
nucleotide database and primers were developed for each target using Primer3Plus 
software and BLAT tools. Primers were ordered from Eurofins Genomics and suspended 
in TE buffer (TekNova) at a concentration of 100uM. RNA was extracted from FACS 
sorted endothelial cell populations via Quiagen RNeasy micro kits. In samples obtained 
from 3D culture, 40µL of proteinase K was added to lysates and an additional incubation 
at 55ºC was added before removal of genomic DNA (as indicated by manufacturer). RNA 
concentration was measured (Take3, BioTek plate reader) and diluted to a homogenous 
concentration across all samples. RNA purity was determined from the 260/280 ratio for 
all samples. 11 randomly selected samples were analyzed for degradation by obtaining a 
RNA integrity number (RIN) from bioanalyzer data. RIN scores of 6+ are considered of 
sufficient quality for use in HT-qPCR, and randomly tested samples ranged in quality from 
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7.0-9.9. RNA was converted to cDNA via a high throughout reverse transcription kit 
(ThermoFischer) and a standard thermocycler via manufacturer’s instructions. High 
throughput qPCR was carried out via the Biomark Fluidigm System with Evagreen 
detection by the Georgia Tech Genomics Core. Three biological replicates of each sample 
were included for analysis. Expression levels of each target were normalized to the 
geometric mean of 2 housekeeping genes with consistent expression (OAZ1, HRPT1) to 
convert raw cycle threshold (Ct) values to ΔCt values. ΔΔCt were obtained via 
normalization to the 2D cultured iHBMEC static mono-culture condition to facilitate 
comparison across BBB models Fold change values were obtained by taking 2- ΔΔCt . 
4.2.6 Statistics 
Detailed discussion of data handling and statistical analysis can be found in Section 
6.5. Briefly, data are presented as mean values ± standard error of the mean (S.E.M.) for 
N=3 replicates, unless otherwise noted. All statistical analysis was performed in GraphPad 
Prism software.  For comparisons of the expression profiles of two groups, a Wilcoxon 
matched pairs signed rank test was used. For comparisons of the expression profiles of 
more than two groups, a Friedmans’ test was used in conjunction with a Dunn’s post-test 
to correct for multiple comparisons. When applicable, p values were adjusted for multiple 
comparisons.  p < 0.05 was considered the cutoff for statistical significance. 
4.3 Results and Discussion 
HT-qPCR was performed in the Georgia Tech Genomics Core. Results were 
reviewed and failed samples and assays were removed prior to data processing and 
analysis. Details regarding the removal of failed samples and assays can be found in 
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Section 6.4.2. After removal of fails, 63 targets and 12 sample groups (N=2-3) remained 
for analysis.  
4.3.1 MLS-BBB Culture Increases Expression of Specializations Relative to 2D Culture 
Our results confirm our hypothesis that an increase in physiological relevance of in 
vitro model design results in an increase in the expression of BBB relevant endothelial cell 
specializations as indicated by the significant upregulation of 26 specializations relative to 
2D static mono-culture of iHBMECs. Subgroup analysis indicates that culture in MLS-
BBB devices significantly increases the expression of major drug resistant proteins, 
junctional proteins, and transporters.  
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Figure 15. Expression profile for tri-culture MLS-BBB device (LEAP) is significantly 
better than 2D control. (A) Radar plot depicting the fold change in expression of each 
target (N=2) relative to 2D static mono-culture of iHBMECs (N=3) indicates that MLS-
BBB culture results in the upregulation of most gene targets. Values above one indicate 
higher expression in MLS-BBB relative to controls, and values below one indicate lower 
expression. (B) Wilcoxon matched pairs signed rank analysis indicates that 2D and LEAP 
expression profiles are significantly different. (C) Subgroup analysis reveals significant 
changes in the expression of drug resistant proteins, junctional proteins, and transport 
proteins in MLS-BBB models. (D) Summary of individual target expression in MLS-BBB 
devices. Targets that are significantly up (green) or down (red) regulated are annotated with 
asterisks to denote magnitude of p-value. n.s. – not significant.  
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4.3.2 Direct Cell Contact Increases Physiological Relevance of In Vitro Models 
One of the primary goals of this study was to evaluate the expression of endothelial 
cells specializations in different culture conditions to enable us to quantify the relative 
strengths and weaknesses of our MLS-BBB. In order to do this, each culture condition was 
separately assessed for its performance relative to 2D static mono-culture of iHBMECs to 
obtain an expression profile across all targets. Expression profiles were then compared 
using statistical methods to determine whether they were significantly different between 
sample groups.  Our results indicate that all three tri-culture models (TWEAP, SPEAP, 
LEAP) exhibit significantly more expression of the specialization targets compared to 2D 
controls (Figure 16 D-F). Furthermore, comparison of TWEAP, SPEAP, and LEAP 
expression profiles indicates that both LEAP and SPEAP have significantly higher target 
expression than TWEAP, but that there is no statistically significant difference between the 
performance of SPEAP and LEAP models (Figure 16 B). This finding supports our 
hypothesis that direct cell contact will result in an increase in the expression of relevant 
specializations.  
Additional investigation via subgroup analysis revealed that the expression profiles 
for the junctional protein category of targets were significantly different between TWEAP 
and SPEAP groups but not between LEAP and SPEAP groups or LEAP and TWEAP 
groups. This result was not expected as it is well established that exposure to flow leads to 
the significant upregulation of junctional associated proteins in endothelial cells [120]. 
However, when the difference in the models and their seeding protocols are considered, it 
is likely that the result is due to either a lack of confluence in the MLS-BBB model, 
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administration of flow for too short a period before harvesting, or too little shear stress (i.e. 
flow rate not sufficiently high).   
Such similar results between LEAP and SPEAP models seem to indicate that direct 
cell contact is more critical to upregulation of key specializations than other critical 
parameters such as the presence of relevant ECM proteins, physiologically relevant cell 
geometries, and exposure to flow. Follow up experimentation over longer culture periods 
and with variable shear stress conditions could potentially clarify these results further.   
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Figure 16. Comparison of TWEAP SPEAP and LEAP models. (A) Radar plot depicting 
the spread of expression profiles for tri-culture transwell (TWEAP, N=3), spheroid 
(SPEAP, N=3) and LEAP (N=2) models. (B) SPEAP and LEAP models both provide 
significant increases in the expression of relative specializations compared to TWEAP 
models when examined across all targets (C) Comparison of the expression profiles of 
junctional associated proteins indicates that SPEAP significantly outperformed TWEAP 
culture in that category, but was not significantly better than LEAP culture in that category. 
(D-E) Individual comparison of each model to the 2D control case indicates that all three 
tri-culture models provide significant increases in the expression of markers relative to 2D 
controls. (F) Summary of targets determined to be significantly up or down regulated in 
models relative to 2D static culture controls. 
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4.3.3 MLS-BBB Model Response to Inflammatory Signals  
In order to begin to assess the functional utility of our MLS-BBB, we administered 
40ng/mL of tumor necrosis factor alpha (TNFα) in media to tri-culture MLS-BBB models. 
After 24 hours of exposure to TNFα supplemented media, endothelial cells were harvested 
from all cultures and evaluated for expression changes for targets. TNFα is an 
inflammatory signaling molecule involved in recruiting leukocytes and other immune cells 
to sites of injury.  In the context of the BBB, inflammatory cytokines such as TNFα have 
been demonstrated to be involved in the activation of endothelial cells, the presentation of 
an inflammatory phenotype, and extravasation of immune cells [160]. Upon exposure to 
TNFα, transcription factors are activated that induce an increase in the expression of 
relevant cell adhesion molecules (VCAM1, ICAM1) [161] on the surface of endothelial 
cells. TNFα has also been shown to induce the degradation of junctional proteins (VE-
Cadherin, ZO-1, ZO-2) [162, 163].  
Addition of TNFα to tri-culture MLS-BBB culture results in a significant change 
in the expression profile across all targets (Figure 17 A-B). Our results further indicate 
that adhesion molecules ICAM1 and VCAM1 are significantly upregulated after exposure 
to TNFα. (Figure 17 C). Subgroup analysis of the expression profiles of each 
specialization category did not yield significant results; however, the junctional protein, 
signaling, and cytoskeletal protein groups had noticeably lower p-values than the 
remaining groups (p~0.15 vs. p~0.5-0.999). This could potentially indicate that the 
expression profiles of these categories are trending towards being significantly different 
and that repetition of the experiment with longer TNFα exposure times could potentially 




Figure 17. MLS-BBB device response to the administration of TNFα. (A) Radar plot 
comparing the expression profiles of tri-culture MLS-BBB (LEAP, N=2) and tri-culture 
MLS-BBB devices exposed to TNFα administration (LEAP Alpha, N=2) (B) Direct 
comparison of LEAP and LEAP Alpha expression profiles indicates that there is 
significantly different expression of specialization targets following exposure to 
inflammatory cues (C) ICAM1 and VCAM1 are significantly upregulated in LEAP Alpha 
models (D) Summary of targets determined to be significantly up or down regulated in 
models relative to 2D static culture controls. (E-F) While not significant, analysis of the 
change in expression of targets within each specialization category indicates that the 
expression profiles of markers in the junctional protein, signaling, and cytoskeletal protein 
categories may be trending towards a significant decrease between the LEAP and LEAP 
Alpha groups.  
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4.3.4 Hydrogel Composition Impacts Specialization Expression 
To further assess the utility of our model and the validity of our hydrogel tuning 
study, we altered the composition of our hydrogel in a subset of MLS-BBB devices and 
examined the resulting effect on the specialization target expression profiles. We 
hypothesised that sub optimal hydrogel culture would result in a decrease in the expression 
of relevant endothelial cell specializations due to presence of reactive astrocytes in culture. 
Tri-culture MLS-BBB models made with CnI, Mat, MatTC and CnIMatHy hydrogels were 
included on the HT-qPCR panel for analysis (N=3 per group) with the goal of quantifying 
the effects of optimal (MatTC), and suboptimal (Mat, CnI, CnIMatHy) ECM composition 
on the expression profiles of the endothelial cells. In addition, tri-culture CnI and MatTC 
MLS-BBB models were included in the TNFα study with the goal of determining whether 
appropriate ECM composition could provide a protective effect or enable the more 
appropriate response of endothelial cells to stimulation. Unfortunately, a large number of 
samples failed on our qPCR panel, resulting in a decrease in or elimination of biological 
replicates available for analysis. Of the groups tested, only the MatTC (N=2) and 
CnIMatHy (N=2) sample groups were successfully amplified on the qPCR panel, limiting 
data available for discussion to comparison between the performance of those two models.  
Both the MatTC and CnIMatHy MLS-BBB culture conditions resulted in very 
significant shifts in the expression profiles of iHBMEC cells relative to 2D controls 
(Figure 18, C-D), but when directly compared across all targets, the expression profiles of 
the two ECM compositions are not significantly different (Figure 18, B). Furthermore, 
while the CnIMatHy hydrogel condition exhibited a larger number of significantly 
upregulated specialization targets in comparison to 2D static mono-culture, additional 
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analysis of model performance by subcategory (amyloid transport, junctional proteins, etc.) 
did not reveal any significant differences in performance by category between the two 
groups.  
At first glance, these results seem to suggest the ECM composition is not a as 
critical of a parameter as previously thought, but when considered in context, this result 
not surprising at all given that CnIMatHy hydrogels were originally selected for inclusion 
in this study based off of literature evidence indicating their suitability for the non-reactive 
culture of astrocytes despite the inclusion of CnI  [84].  
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Figure 18. MatTC and CnIMatHy hydrogels are both suitable candidates for in vitro 
BBB model development. (A) Radar plot comparing the expression of each specialization 
target in MatTC MLS-BBB (N=2), CnIMatHy MLS-BBB (N=2), and 2D static 
monoculture of iHBMEC cells (N=3). (B) The expression profiles of the two ECM 
compositions are not significantly different and (C-D) both cases results in a significant 
increase in marker expression relative to 2D culture (E) Summary of targets that are up or 





In this work, we characterized our MLS-BBB relative to two simple in vitro models of 
the BBB to assess whether our device provided a marked improvement in the expression 
of BBB relevant endothelial cell specializations. Our results further support literature 
evidence that direct contact between cellular constituents is critical for proper expression 
of specializations. Additionally, we demonstrated the functional utility of our device 
through analyses of model response to TNFα administration. Finally, we evaluated the 
degree to which ECM composition impacts the expression of relevant specializations by 
comparing the expression profiles obtained from MLS-BBB devices made with MatTC 
and CnIMatHy hydrogels. While MLS-BBB devices cultured in CnIMatHy exhibited a 
larger number of significantly upregulated targets relative to 2D controls, ranked 
comparison and sub group analysis did not reveal and significant differences in the 
performance of the models for any category tested (transport, drug resistance, etc.) 
indicating that both MatTC and CnIMatHy are suitable ECM compositions for use in vitro 
BBB culture.  
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 Summary 
The work presented in this thesis constitutes a significant contribution to the fields 
of tissue engineering and OOAC development by producing the first in vitro model of the 
BBB to simultaneously incorporate both astrocyte and pericyte cells with a perfusable 
lumen of brain endothelial cells. Furthermore, the comprehensive characterization of our 
models relative to commonly used in vitro BBB models enables us to weight the relative 
strengths afforded by our model (increased relevance) with its weaknesses (increased 
complexity, cost, etc.). This data provides insight that will enable the intelligent design of 
subsequent iterations of this and other devices and ultimately aid researchers in better 
balancing simplicity and physiological relevance when selecting an in vitro model of the 
BBB for preliminary drug studies.  
5.1.1 Development of MLS-BBB 
To develop our MLS-BBB, we first determined the most suitable 3D culture 
conditions for the most appropriate culture of astrocytes by tuning the composition of two 
commonly used hydrogel systems (Matrigel and Collagen I) to minimize the upregulation 
of genes that are indicative of a reactive gliosis state. We then used our tuned hydrogel 
(MatTC) in conjunction with a previously described sacrificial element method to craft 
cylindrical channels through the astrocyte embedded hydrogels. Channels were then 
serially seeded with pericyte and endothelial cells to form our MLS-BBB. After lumen 
establishment, flow was administered to MLS-BBB devices via pump-facilitated gravity 
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driven flow (PF-GDF) to maintain a constant wall shear stress of 4 dynes/cm2, a value 
consistent with estimates of in vivo conditions. Our MLS-BBB facilitates the incorporation, 
relevant arrangement, and direct interaction of all three cell types as was visually confirmed 
via histological staining for distinct cell proteins (ZO-1, αSMA, GFAP). Histological and 
morphological observation confirms the contact of astrocyte endfoot projections with 
endothelial cells, the presence of tight junctions between endothelial cells, and the lining 
of endothelial lumens by pericyte cells.  
5.1.2 Characterization of MLS-BBB 
In order to evaluate the relevance of our model, we utilized high throughput qPCR 
techniques to simultaneously measure the relative expression of 81 endothelial cell 
specializations demonstrated to be differentially or characteristically expressed at the BBB. 
To enable meaningful interpretation of our data, we also analyzed endothelial cells from 
transwell and spheroid models, two simple, high throughput models that are currently used 
for preliminary drug studies. Our results indicate that our model provides a significant 
improvement over transwell culture models, and that direct cell contact in vitro is critically 
important for the expression of BBB relevant specializations. Further experimentation with 
our MLS-BBB revealed that model can respond appropriately to inflammatory stimulation 
(TNFα) via the upregulations of cellular adhesion molecules (ICAM1, VCAM1) and that 
small perturbations to the hydrogel composition can be made without negatively impacting 




5.2 Future Directions 
5.2.1 Ongoing Research 
One of the ultimate goals of OOAC model development is eventual adaptation for 
preclinical assessment of novel drug compounds [12]. Despite an abundance of OOAC 
BBB models available in the literature, to date, very few have been employed in the context 
of a preclinical study for the development of a new drug candidate. To this end, we propose 
the use of our MLS-BBB in parallel with transwell culture and ex vivo assays for the 
evaluation of a novel, multifunctional nanomedicine for the treatment of SSH driven MB. 
Through such experimentation, we aim to demonstrate the utility of our MLS-BBB model 
for preclinical studies and compare the functional utility of our MLS-BBB to that of 
transwell culture and ex vivo approaches, while also assessing whether functionalization 
with ApoA1 will increase penetrance of LPNP NPs through the BBB. We believe that such 
rigorous, parallelized, evaluation of OOAC models in the context of preclinical studies is 
critical for the continual improvement of OOAC devices.  
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Figure 19. Experimental workflow for the evaluation of multifunctional 
nanomedicines with MLS-BBB. Libraries of custom, drug loaded, protein functionalized lipid 
polymer nanoparticles will be microfluidically synthesized for use in in vitro evaluation of their 
ability to cross the BBB and induce tumor cell death. Our MLS-BBB will be used in parallel with 
TWEAP permeability assays to assess the degree to which particles can penetrate the BBB. Ex vivo 
slices of PDX mouse tumors will be used to evaluate the therapeutic effect and tumor targeting 
abilities of drug loaded nanoparticle administration. Results from in vitro and ex vivo study 
approaches will be used to determine if in vivo validation is warranted or if re-design of 
nanoparticles is necessary.  
 
5.2.2 Short Term Directions 
By virtue of its demonstrated increased physiological relevance relative to standard 
models (static monoculture, tri-culture transwell), our MLS-BBB could be used “as is” to 
study a wide range of topics including BBB formation and embryogenesis. Additionally, 
our MLS-BBB could be altered to study pathophysiological BBBs such as those found in 
AD, PD, and MB. As discussed in previous sections, our MLS-BBB could be further 
improved by facilitating the inclusion of more NVU cell types (microglia and neurons) and 
through modification to a higher throughput platform. When combined with insight gained 
from our ongoing work, such modifications could enable the widespread implementation 
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of our MLS-BBB in the fields of tissue engineering, drug discovery, and drug development. 
Furthermore, as one of the eventual goal of OOAC research is the realization of a “human-
on-a-chip” platform for use in drug discovery and evaluation, a potential future direction 
of our model is connection and integration with other OOAC model systems. Gut-on-a-
chip model systems are prime candidate for integration with BBB-on-a-chip due the 
demonstrated link between gut health and Parkinson’s disease (PD) [164, 165] and the 
demonstrated ability of the gut to impact BBB function through hormone secretion and 
microbe composition [166], but the potential applications are numerous and varied due to 
the ability of OOAC culture to enable detailed mechanistic observation of cellular 
phenomena.   
5.3 Conclusion 
In this work, we present a novel in vitro model of the BBB (MLS-BBB) that 
simultaneously incorporates three neurovascular unit cell types (endothelial, astrocyte, 
pericyte) in a 3D hydrogel system tuned to mimic the properties of brain extracellular 
matrix. Our model enables the formation of perfusable endothelial cell lumens that are 
lined with pericytes and wrapped with astrocyte endfoot projections. Through the 
comprehensive characterization of our MLS-BBB we have demonstrated that in vitro 
models that facilitate the direct interaction of cellular constituents increase the expression 
of BBB relevant endothelial cell specializations. Furthermore, we have demonstrated that 
our MLS-BBB responds appropriately to inflammatory stimulation with TNFα, indicating 
its potential suitability for the preliminary evaluation of drug effects. Taken together, our 
work constitutes a significant contribution to the fields of tissue engineering and organ-on-
a-chip development. 
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CHAPTER 6. SUPPLEMENTARY MATERIAL 
6.1 Fluorescent Activated Cell Sorting (FACS)  
6.1.1 FACS is Necessary for Reliable qPCR Data Interpretation 
The gene targets selected for quantification in our MLS-BBB characterization study 
are all endothelial cell specializations. These targets are varied in nature and function, and 
in some cases, are also expressed in astrocyte and pericyte cells at levels sufficiently high 
to distort or falsely inflate qPCR result interpretation. Similarly, there is the potential for 
data distortion if HBVP or HA genetic material is present in an RNA sample thought to be 
pure iHBMEC cDNA. Such contamination could lead to falsely deflated expression values.  
Thus, the reliable purification of iHBMEC cells from co-culture conditions was critical to 
this work.  
 
Figure 20. Schematic illustration of the effect of poor sorting on qPCR results. (A) 
Schematic of RNA processing workflow and (B) an example of the difference in qPCR 
data results obtained from pure and mixed cell samples given raw Ct values of 14, 10, 20, 
and 18 for the control sample, pure experimental sample, mixed experimental sample, and 
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housekeeping gene, respectively. The presence of non-relevant cells will falsely deflate 
obtained fold change results relative to the control. More explanation of qPCR data 
processing and the calculation of fold change values from raw Ct values can be found in 
Section 6.4.1. 
6.1.2 FACS Protocol  
MLS-BBB devices we disassembled via careful peeling of the PDMS housing from 
the glass slide to expose the hydrogel. The hydrogel containing the formed lumen was then 
carefully retrieved and placed in a 2mL Eppendorf tube for dissolution with a 1:1 mixture 
of trypsin (0.1%) and Dispace (Corning). Tubes were placed under incubation and slight 
rocking for 30 minutes. Samples were further disaggregated via passage thru a 40μm cell 
strainer, and dissolution of the lumen constructs to a single cell suspension was verified 
via microscopic inspection of tubes before proceeding with staining.  Single cell 
suspensions were stained for sorting via flow cytometry in a FACS buffer composed of 
PBS (1X, Gibco) supplemented to contain 2% BSA, 1mM EDTA and 0.1% sodium azide. 
Endothelial cells were selectively stained with an Alexa Fluor® 647 conjugated anti-
human CD31 Antibody (BioLegend) according to manufacturer instructions and were 
sorted on a BD FACS ARIA Fusion flow cytometer system (Georgia Tech Core Facilities). 
Positivity was selected by comparing to unstained sample to account for background auto 
fluorescence.  Prior to sorting experimental samples, test sorts were conducted in which 
captured cells were sorted into media, re-plated, and expanded to confirm that a pure 
endothelial cell population was being captured. When sorting for data collection, cells with 
the fluorescent marker were captured and sorted directly into RLT buffer to preserve RNA 




Figure 21. Example of FACS set up. (A) Schematic examples of scatter and intensity 
plots observed during sorting with singlet population indicated. (B) When no cells are 
tagged, only a single peak is observable. (C) Addition of the anti-CD31-647 antibody 
produces a peak in the appropriate range. 
6.2 Isolation of RNA from 3D Cultured Cells 
In this work, we utilized the RNeasy Plus Micro kit (Qiagen) for all RNA extraction 
due to the limited number of cells available for recovery from our culture systems. High 
quality RNA is essential to successful qPCR (see MIQE guidelines [167], also Section 
6.4); thus, the purity, yield, and stability of sample RNA was assessed via established 
methods before proceeding to qPCR. The purity and yield of samples were obtained via 
spectrophotometric analysis (BioTek Plate Reader, Take3 Attachment) and sample 
stability was assessed via a chip based capillary electrophoresis system (Agilent 
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Bioanalyzer, Georgia Tech Genomics Core).  Thresholds for each parameter are as follows:  
RNA yield must be at least 2ng/μL, RNA purity as determined by the 260/280 ratio should 
be >1.6 (pure RNA~2), and RNA integrity number (RIN) should be 6+ if samples are to 
be reliably used in qPCR analysis.  
Unexpectedly, upon analysis of our samples, we noted that RNA extracted from 3D 
culture in hydrogels had significantly lower RIN scores than those obtained from 2D 
culture even when kit instructions were followed exactly (Figure 22 B). We were quite 
surprised with this result, given that our experimental parameters fell well within the 
working range of the kit. Qiagen technical support indicated that the degradation was most 
likely due to the incomplete removal of ECM components from samples during the kit 
workflow and recommended the addition of a proteinase K incubation step (40μL/sample, 
15 minutes, 55ºC) when extracting RNA from 3D cultured samples. Addition of the 
proteinase K incubation was successful for most of the 3D culture conditions tested, with 
the RIN scores as high as 9.8 on some samples. Interestingly, addition of proteinase K 
alone was not sufficient in cases where the ECM was composed predominantly of collagen 
I. Upon further consultation with Qiagen technical support, it was determined that an 
additional processing column (Qiashredder) is necessary when relatively high 
concentrations of fibrous proteins like collagen I are present in a sample. Addition of the 
additional Qiashredder processing step (in conjunction with the proteinase K incubation) 
facilitated the recovery of pure, stable RNA from samples cultured in collagen I.  
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Figure 22. Optimization of RNA isolation protocol. (A) Example of electrophoretic 
traces of intact, partially degraded, and strongly degraded RNA samples from Agilent 
Biosystems (https://www.agilent.com/cs/library/applications/5989-1165EN.pdf)(B) 
Exactly following RNeasy Plus Micro kit instructions resulted in low quality RNA product 
due to incomplete removal of residual ECM components during purification (C) Addition 
of a proteinase K incubation to the RNA isolation workflow for samples obtained from 3D 
ECM enabled recovery of high quality RNA. (D-F) Summary of RNA purity, yield and 
quality of samples assessed for markers of reactive gliosis. All samples tested had 
acceptable (D) purity, N=6 per sample (E) yield, N=6 per sample and (F) stability values, 
N=5. Red dotted lines indicate minimum threshold for each parameter. (F) For RIN scores, 
5 samples were randomly selected from the 42 total samples to assess purity. RIN scores 




6.3 Development of qPCR Primers 
6.3.1 Primer Design 
Gene targets were selected from literature review and the gene name for each target 
was obtained from the GeneCards database (genecards.org). Complete CDS sequences for 
each gene target were obtained from the NCBI (ncbi.nlm.nih.gov) nucleotide database and 
were copied into the Primer3Plus software (bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi) to generate primers. Suggested primer pairs were then 
analyzed in an online BLAT tool to determine their suitability for use 
(http://genome.ucsc.edu/). Primers selected had 20 base pairs, a melting temperature of 
60ºC, produced a product size between 150-200 base pairs, and returned a single match in 
BLAT analysis. Chromosomal location of the target was confirmed for each target using 
NCBI and other genomic resources. 
6.3.2 Primer Details 
Designed primers were ordered dry from Eurofins Genomics and resuspended to a 
homogenous concentration of 100μM in TE buffer before use. Dry primer plates were 
warmed to room temperature before resuspension with buffer and were incubated at 4ºC 
with gentle shaking overnight to ensure complete dissolution of primers. Once 
resuspended, primers were aliquoted into multiple plates for use to prevent the necessity of 
multiple free thaw cycles. Forward and reverse sequences for each primer pair used as well 
as primer details (gene name, NCBI reference sequence used for primer development, 
category for use) can be found in Table 4. 
 91 
Table 4. Summary of primer pairs used in HT-qPCR analysis  
Gene (Homo Sapien) 
NCBI Reference 
Sequence 
Category Forward Primer Reverse Primer 
LRP1 NM_002332.2 Amyloid Transport ggtactacctgcgcaagctc cacattgctcccgttaaggt 
APLP2/YWK-II NM_001642.2 Amlyoid Transport ttccaagccatggttaaagc ctttgttctcagcacggaca 
LRP1b NM_018557.2 Amlyoid Transport cggcatttacagtccctgat tccactgctagccctctgat 
CCL2 NM_002982.3 Amlyoid Transport ccccagtcacctgctgttat tggaatcctgaacccacttc 
GJB6 NM_001110219.2 Astrocyte Marker tttctgcgtctgtgatttgc gcttgggaaacctgtgattg 
AQP4 NM_001317384.1 Astrocyte Marker agatcagcatcgccaagtct aaccaggagaccatgaccag 

























ACTB NM_001101.2 Cytoskeletal Protein  agaaaatctggcaccacacc agaggcgtacagggatagca 
VIM NM_003380.3 Cytoskeletal Protein  ccctcacctgtgaagtggat ctcaatgtcaagggccatct 
UTRN NM_007124.2 Cytoskeletal Protein  gagctgaatgttgtgctgga ttctcaggcaggacctctgt 
ABCB1/MDR1 (Pgp) AF016535.1 Drug Resistance tgattgcatttggaggacaa ccagaaggccagagcataag 
ABCC1 NM_004996.3 Drug Resistance aggtggacctgtttcgtgac accctgtgatccaccagaag 
ABCC2 NM_000392.4 Drug Resistance agagctggcccttgtactca agggacaggaaccaggagtt 
ABCC3 NM_001144070.1 Drug Resistance ttttctttgtcacccccttg aaaggatcttggagcggaat 
ABCC4/MRP4 NM_005845.4 Drug Resistance ggcttgtgctctgaaaaagg ctgagaggatcgtccaggag 
ABCC5 NM_005688.2 Drug Resistance agctgggtacttccagagca tctgtcaacagccactgagg 

















Flt-1 NM_002019.4 Growth Factor tttggatgagcagtgtgagc cggcacgtaggtgatttctt 
PTN / HARP BC005916.1  Growth Factor gaaaatttgcagctgccttc ctgggtcttcatggtttgct 
IGF-2 NM_000612.5 Growth Factor cgttgaggagtgctgtttcc ggactgcttccaggtgtcat 
IGF-BP3 M31159.1 Growth Factor cctgccgtagagaaatggaa aggctgcccatacttatcca 
FGF-19 AF110400.1 Growth Factor tcggaggaagactgtgcttt ggcaggaaatgagagagtgg 
Tomoregulin/TMEFF2 AB004064.1 Growth Factors ccagtttggtgcagaatgtg ttgacatcgacccaaagaca 
OAZ1 AY865622.1 Housekeeping Gene gagccgaccatgtcttcatt cccgaagactctctctcgaa 
PMM1 NM_002676.2 Housekeeping Gene tagagtgcagatcggtgtgg caggtggttctggatggtct 
HPRT1 NM_000194.2 Housekeeping Gene gaccagtcaacaggggacat cttgcgaccttgaccatctt 
RPL30 N/A [168] Housekeeping Gene acagcatgcggaaaatactac aaaggaaaattttgcaggttt 
PSMB6 NM_002798.2 Housekeeping Gene cctattcacgaccgcatttt cccggtatcggtaacacatc 
CLDN12 NM_001185072.2 Junctional Protein ctccccatctatctgggtca tgggtggatgggagtacaat 
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CLDN3 NM_001306.3 Junctional Protein caacaccattatccgggact cttggtggccgtgtacttct 
CLDN5 NM_001130861.1 Junctional Protein gttttacgacccgtctgtgc gtacttcacggggaagctga 
ZO1/TJP1 NM_003257.4 Junctional Protein tgaggcagctcacataatgc gggagttggggttcataggt 
ZO2/TJP2 NM_004817.3 Junctional Protein gggatattgcaggcacagtt cgctgtctcccttcttgaac 
ZO3/TJP3 NM_001267560.1 Junctional Protein atcgagcgcctcaactatgt agaggtggctgctgtgtttt 
CTNNB1 NM_001098209.1 Junctional Protein gaaacggctttcagttgagc ctggccatatccaccagagt 
SRGN NM_002727.1 Junctional Protein cgctgcaatccagacagtaa ccgaagcctgatccagagta 
VE-cadherin X79981.1 Junctional Protein cagcccaaagtgtgtgagaa cggtcaaactgcccatactt 
PECAM-1 M28526.1 Junctional Protein atgatgcccagtttgaggtc acgtcttcagtggggttgtc 
F11R/JAM-A BC001533.2 Junctional Protein agctatggggaggtcaaggt cccatctttgaaccaggtgt 
GJC1 NM_005497.3 Junctional Protein cacccgttttatgtgtgcag gagtctcgaatggtcccaaa 
OCLN NM_002538.3 Junctional Protein tggcaaagtgaatgacaagc gcaggtgctctttttgaagg 
CTNNA1 NM_001903.3 Junctional Protein aagtagaagcagccgtggaa cgtcctgcttctgacatcaa 
JAM2 NM_021219.3 Junctional Protein agaagtgatgcggggaaata ccacagttccactcagagca 
JUP NM_002230.2 Junctional Protein aaggtgctatccgtgtgtcc gacgttgacgtcatccacac 
MARVELD2 NM_001038603.2 Junctional Protein aaagaggctgacgcagtgtt gctccaccacacccagtatt 
PODXL XM_004727.1 Junctional Protein gagcagtcaaagccaccttc tggtcccctagcttcatgtc 
ITM2aB17:H27 NM_004867.4 Junctional Protein ccgtggagagatgtgctttt tgctgcagggtcactatcag 
RGS5  AF030108.1 Pericyte Marker cgtgattccctggacaaact tttgccttctcagccatctt 
PGDFR beta M21616.1 Pericyte Marker cactgcctgtcccctatgat acagtctgcactgcgttcac 










































































































TFRC AF187320.1 Transport gctgccagctttactggaga ttgtcaatgtcccaaacgtc 
PLTP NM_006227.3 Transport ttctgtggacgagcttgttg gaaggccacatacaccatcc 
ATP1A2 NM_000702.1 Transport cgcaaataccaagtggacct aagcagaggatagccccaat 
xCT/4F2hc/ SLC3A2 NM_001012662.2 Transport tcctgccttagcttccaaga cgggctctaactcattcagc 
Slc16a2 NM_006517.4 Transport gcctgcgctacttcacctac cttgatcttatcccccagca 
Slc22a5 NM_001308122.1 Transport ggattgttgtgccttccact aaagcccaaaatagcccact 
Slc22a7 NM_006672.3 Transport gagtcctgagcagcaccttc tacctgtgggcctctttcac 
Slc22a8/OAT3 NM_004254.3 Transport caccgtcatcttgaatgtgg accaaccagcgtatggactc 
Slc2a13 NM_052885.3 Transport cagactcagaaggcccgtag tgggggataactcagcattc 
Slc30a1/ZNT1 NM_021194.2 Transport tgctggaagcagaatcattg gttctgcaggcaagttcaca 
Slc38a3/SNAT4 NM_006841.5 Transport ttcgggatgtcagtgttcaa gtagcccagctgctcatagg 
Slc38a5/SNAT5 NM_033518.3 Transport ccacaatgaaacagcaatgg cgtatagatgggcagcacct 
Slco1a2/Oatp1a2 NM_134431.3 Transport tttggcgctttaatggattc aaggctggaacaaagcttga 
Slco1c1/BSAT NM_001145946.1 Transport tggttgtcaaacctccaaca agctgtggcttaatgcacct 
SlcO2B1 NM_007256.4 Transport ggcatccagttcatgttcct ggtttcggagcaggtcatta 
EAAT1/SLC1A3 NM_001289940.1 Transport catgcacagagaaggcaaaa gtcacggtgtacatggcaag 
EAAT2/SLC1A2 NM_001195728.2 Transport cgccatctttatagcccaaa agcaggctgatgtcctctgt 
EAAT3/SLC1A1 NM_004170.5 Transport cctggtgtcacccagaaagt ggaggcttcacttcttcacg 
GLUT1/SLC2A1 NM_006516.2 Transport cctgcagtttggctacaaca taacgaaaaggcccacagag 
TAUT (SLC6A6) NM_003043.5 Transport agggttatcgtcgggaaatc agaatgcaacccacaaaagg 
MCT1 AL162079.1 Transport tccagctctgaccatgattg gcccccaagaattagaaagc 
LAT1 (SLC7A5) NM_003486.5 Transport gaaggcaccaaactggatgt gaagtaggccaggttggtca 
CAT-1 AF078107.1 Transport atggccttcctctttgacct ggtgcttgccaattcatttt 
CNT2 (SLC28A2) NM_004212.3 Transport gccttgtgcaatgggtagtt agagtgtcatgtccccaagg 
IGF1R NM_000875.4 Transport aaccccaagactgaggtgtg tgacatctctccgcttcctt 






6.4 HT-qPCR Data Handling 
6.4.1 General Introduction to qPCR 
The real time quantitative polymerase chain reaction (qPCR) is a technique used to 
quantify a specific portion of DNA using target specific nucleotide sequences called 
primers. qPCR reactions are widely used for the quantification gene expression due to their 
specificity and sensitivity and they are often cited as the most sensitive and reliable method 
for the detection and quantification of nucleic acids.  qPCR quantification is based on the 
detection of fluorescent reporter molecule in real time. In each qPCR reaction, 
amplification is carried out via temperature cycling through a protocol designed to 
sequentially denature double stranded DNA, anneal target specific primers, and elongate 
the target strand. Fluorescent molecules (Eva Green) are inserted into each newly formed 
double stranded DNA product, enabling detection of target amplification over time. The 
cycle at which the amplification of a target becomes detectable is noted by the machine as 
the cycle threshold (Ct) value for that sample and can be used in the relative quantification 
of the expression of targets across different samples [169, 170].  
Due to the increasing frequency of use and variability in protocols used for qPCR 
analysis, a set of guidelines detailing the minimum information for publication of 
quantitative real-time qPCR Experiments (MIQE) was published in 2009 [167]. The MIQE 
guidelines, as well as information provided by the Georgia Tech Genomics Core was used 
in the development of all experimental procedures and protocols to ensure reliability of 




Figure 23. Fundamentals of qPCR. (A) Schematic of amplification and detection process 
used in qPCR. Double stranded DNA is denatured to enable the attachment of target 
specific primers. Enzymes then catalyze the recruitment of complementary base pairs to 
the segment identified by the primer pair. Amplification of target strands is detected via 
the incorporation of a double strand specific fluorescent probe (Eva Green). Each time the 
cycle of the machine repeats, the reaction begins again, resulting in a two-fold increase in 
the abundance of the selected target sequence per amplification cycle. (B) Example of 
amplification curves obtained during qPCR. For a given target, there will be a specific 
cycle number at which the fluorescent intensity of the EvaGreen dye reaches a threshold 
value. This cycle number is denoted as the cycle threshold value (Ct) and is used to quantify 
the relative expression of targets across samples. (C) The Ct value of each sample is 
normalized with housekeeping genes to account for variability in starting material 
concentration (Eqn. 6), before being normalized to a control for relative quantification 






6.4.2 qPCR Data Processing 
Before processing data to obtain fold change values, we first examined the HT-
qPCR assay results to identify and remove failed samples and targets. It is critical that assay 
fails be identified and removed prior to data processing or results can be significantly 
skewed from the inclusions of default “fail” Ct values (999).  
Samples were classified as failed assays if the sample failed to amplify any of the 
4 endothelial cell specific markers included on the panel (Samples: 24, 31-33, 41, 44-46, 
48, 50-52, 56,57, 59, 60, 64, 67-75, 80, 85-87, 94) or if the sample failed to express more 
than 50% of targets tested (Note: Distinct cell markers were excluded from this calculation. 
Samples: 25, 27, 80, 89). Samples 76-96 were included for a lab mate (S. Ahn) and are not 
relevant to this study, so they were also removed prior to data analysis. Failed samples 
were deleted from the results table before removal of targets.  
Targets were considered failures if they failed to amplify in more than one of the 
TWE/static culture iHBMEC replicates needed for data normalization to 2D culture 
(Targets: SELE, Slc22a8/OAT3, Slco1a2/Oatp1a2), if they failed to amplify in the assay 
positive control samples (Targets: GJB6), if they failed to amplify in the commercially 
available human cDNA positive control sample (Targets: AQP4, ALDH1L1, ABCC3, 
ATP1A2, EAAT2, CNT2), or if the total number of failed assays for that target was more 
than one standard deviation above the average number of failed assays per target (Targets: 
EAAT1/SLC1A3, SlcO2B1, Slco1c1/BSAT, ITM2aB17:H27, ZO3, FGF-19, HARP, PLP-
1, PROM1, SELE).  
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Figure 24. Identification of failed assays from HT-qPCR array. Failed samples and 
failed targets were identified (red cells) and removed prior to data processing and analysis 
to prevent distortion of results. Failed assays are designated a placeholder Ct value of 999 
(blacked out cells) that will skew ΔCt, ΔΔCt, and fold change values if they are not 
removed.   
After the removal of all assay fails, fold change values were obtained from the 
equations listed in Figure 24. Briefly, housekeeping genes were selected from a review 
relevant literature, and careful attention was paid to be sure that they were suitable for study 
[168]. As an extra precaution, extra housekeeping genes were included on the panel to 
ensure that more than one would be available for normalization of data. Ct values were 
normalized to the geometric mean of at least two housekeeping genes (BBB studies: OAZ1, 
HRPT1; HA study: OAZ1, HRPT1, PMM1) to account for variation in the amount of 
genetic material present in each sample to obtain ΔCt values. ΔCt values were then 
converted to ΔΔCt values via subtraction of the ΔCt of the control sample (either 2D HA 
or static, mono-culture iHBMECs) from the ΔCt of each sample for each target. Fold 
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change values were then calculated by taking 2- ΔΔCt. All data processing was performed in 
Excel before being exported for importation into statistical analysis software. 
 
Figure 25. Heat map of fold change values sorted by specialization category (rows) 
and sample (columns). Fold change values are color coded with conditional formatting in 
excel with the highest fold change relative to 2D static culture indicated by yellow, and the 
lowest fold change relative to 2D static culture indicated by purple.  
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6.4.3 Statistical Analysis of Fold Change Data 
Statistical analysis methods are predicated on assumptions that must hold true for the 
analysis to be robust and accurately reflect the data in question. Although qPCR is widely 
used, statistical analysis performed on results varies widely from study to study. The 
primary reason for the lack of a gold standard practice for determining the statistical 
significance of relative expression (fold change) data is the ambiguity regarding the 
underlying probability distribution of relative expression data [171]. When small sample 
numbers are used (N<20) and the underlying probability distribution is unknown, it is 
recommended that re-sampling methods be used to assess percentiles and the related 
statistical significance of the data [172].  
After careful review of the relevant literature, we chose to use the BootstRatio online 
tool to determine which targets from our data sets were significantly up or down regulated 
relative to the control group [167, 169-176]. The BootstRatio tool is based on bootstrapping 
resampling and permutation methods that enable the assessment of the significance of gene 
expression ratios without any assumptions regarding the underlying probability 
distributions of the data set [172]. The BootstRatio online tool has two functionalities. It 
can be used to determine which targets are significantly up or down regulated in given a 
single sample (already normalized to a control) or it can determine which targets are 
significantly up or down regulated between two samples.  
In our analysis, we used the BootstRatio tool to identify targets that had significantly 
higher or lower expression between two samples. All other analysis was performed via 
GraphPad Prism software. Wilcoxon matched pairs singed rank tests were used to 
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determine if two expression profiles (i.e. all target expression in a given sample, or 
expression for a subset of targets within a category) were significantly different between 
two samples. A Friedmans’ test with a Dunn’s post-test to account for multiple 
comparisons was used to compare the expression profiles of three or more groups. All 
reported p-values are two-tailed and significance was assigned as follows: not significant, 
n.s.;  *p < 0.05; **p < 0.01 ; ***p < 0.001;  ****p < 0.0001.  
6.5 Proof of Concept Studies 
6.5.1 Media Optimization for Co-Culture Experiments 
Different cell lines have different suggested media compositions for optimal in vitro 
culture. We conducted a proof of concept study to verify that combination of the relevant 
cell specific medias would not negatively impact cell morphology in co-culture models 
containing more than one cell type. From this study, we determined that using 1:1 ratios of 
all relevant cell specific media caused the least observable difference in cell morphologies 
across the various cell types used.   
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Figure 26. Results of media optimization experiment. Morphological changes to cells 
are easily observed when cells are cultured in the wrong cell type specific media, but 
culture in combination media is able to mitigate these changes.  
6.5.2 Formation of Round Sacrificial Elements  
The sacrificial element protocol utilized in this work had previously only been used 
to craft square elements using silicon wafer master molds for soft lithography of element 
molds. Using this method, the authors were able to craft channel geometries with features 
as small as 5μm x 5μm (h x w) [42]. We were successful in adapting this method to produce 
both square and round sacrificial elements ranging in diameter from 50-500μm. However, 
throughout the course of our studies, we noted that square elements cast with better 
resolution and preservation of original injection mold shape due to the difference in the 
substrate properties between silicon wafer molds and 3D printed molds. Additionally, 
round elements require the perfect alignment of injection mod slabs or the channel shape 
can become distorted (Figure 26: Bottom row, middle panel). Literature evidence indicate 
that shear stress plays a larger role influencing endothelial cells than lumen geometry [177], 
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and preliminary experimentation with both square and round sacrificial elements yielded 
indistinguishable results in lumen formation, indicating that square elements could be used 
for future studies to eliminate fabrication issues associated with round sacrificial elements.  
 
Figure 27. XY-plane and YZ-plane views of square and round sacrificial elements. 
Elements were doped GFP and encapsulated in RFP doped Matrigel for imaging. 
Noticeable variability exists in the YZ projections of round elements due to issues with 
injection mold alignment during fabrication (bottom row). Square element injection molds 
do not require alignment, and the resulting shape is more consistent (top row).   
6.5.3 Dose Determination for TNFα Administration to MLS-BBB 
In order to conduct qPCR on recovered cells, it is essential that the administration 
concentration of TNFα is sufficiently high to induce inflammation, but not so high as to 
kill all the cells.  Similar studies are available in the literature, and sources that examined 
similar cells types used concentrations ranging from 50pg/mL - 50 ng/mL [160, 178]. Prior 
to experimentation, we administered various concentration of TNFα to static cultured 
iHBMEC cells to determine the most appropriate dosing concentration for our study. 
iHBMEC cells were seeded into 0.1% gelatin coated wells (96 well plate, 200μL/well, 1E5 
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cells/mL) and allowed to expand for three days prior to experimentation. TNFα was 
prepared in cell specific media at concentrations of 0, 1, 10, 20, and 40 ng/mL. Cells were 
incubated with TNFα media for 24 hours before conducting a Live/Dead assay to visualize 
cell death.  Our results confirmed those found in literature that a dosing concentration of 
40ng/mL would be sufficient to elicit cell death, but not so harsh as to kill all the cells.  
  
Figure 28. Live/Dead staining of 2D cultured iHBMEC cells. Live/Dead assay results 
of TNFα administration to static mono-culture iHBMEC cells indicate that a dosing 
concentration of 40ng/mL should be sufficient to initiate response from models.  
6.5.4 Permeability Studies with MLS-BBB 
While the primary goal of this work was the construction and high throughput 
characterization of a novel in vitro BBB model, the downstream application as a preclinical 
screening tool necessitates compatibility with standard permeability protocol workflows if 
the model is to be useful. Thus, we conducted a proof of concept study to demonstrate that 
our model will facilitate the conduction of fluorescence based permeability assays. 
Protocols for such assays are readily available and have been carried out in similar lumen 
models with good success [110]. 
  Monoculture iHBMEC lumens were grown in MLS-BBB devices for 5 days before 
use in permeability assays. Culture media was supplemented with 5μg/mL fluorescently 
tagged dextran (either 4kDa or 150 kDa) and a shear rate of 1dyne/cm2 was initiated via 
the establishment of a 137 μL volume difference between the reservoirs. Fluorescent 
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images were obtained every 5 seconds for 15 minutes via the time lapse capture function 
on an EVOS FL Auto microscope. Mean fluorescent intensity values in the channel, 
surrounding region, and background were obtained via Image J for N=3 devices and n=10 
measurements in each case. Apparent permeability values were calculated using equation 
9 and compared to previously published results from previous studies.  Our results indicate 
that our mono-culture iHBMEC lumen has apparent permeabilities of 3.17E-6 cm/s (+/- 
2.85E-8) and 3.125E-5 cm/s (+/- 1.0223E-6) for 150kDa and 4kDa dextrans, respectively.  
Comparison to previously published results (Figure 28 D) indicates that our MLS-BBB 
device performs comparably to other models available in the literature [108, 110].  
 
Figure 29. Proof of concept permeability study. (A) Representative images of 150kDa 
TRITC-Dextran permeability in MLS-BBB device. (B) Equation for the calculation of 
apparent permeability where ΔI is the increase in total fluorescence intensity upon adding 
labeled dextran, (dI/dt)0 is the initial rate of increase in intensity as dextran diffuses out of 
the tube into the surrounding gel, and r is the radius of the tube (C) Results of preliminary 
permeability studies conducted with 4kDa and 150kDa tagged dextran. Data depicted are 
mean +/- SEM apparent permeability values (N=3) (D) Excerpt from Booth and Kim study 
[108] indicates that observed permeability values fall within range of expected results.  
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6.5.5 Recovery of All Three 3 NVU Cell Types via FACS 
  As discussed, the function of the BBB is largely dependent on the function and 
health of the supporting cell types of the NVU. Thus, the next logical assessment of our (or 
other) devices would be detailed examination of the health and physiological relevance of 
the support cell types present in culture in addition to the endothelial cells. Preliminary 
protocol development for the purification and recovery of all cells types from co-culture 
was attempted using cell specific probes for each cell type that were successfully used for 
imaging protocols as they were cross listed for use in FACS by the manufacturers 
(HBMEC, Anti-CD31; HBVP, αSMA; HA, Anti-GFAP). Manufacturer instructions for 
dilution and sample preparation were followed exactly and compensation controls were 
used during initialization of FACS sorting protocol development to prevent crossover 
between channels with potentially overlapping spectra.  
Preliminary results of staining are shown in Figure 29. Of the probes tested, only 
the CD31 probe performed well. The GFAP probe appears unable to bind, and the αSMA 
peak separation was poor. Consultation of the Human Protein Atlas 
(http://www.proteinatlas.org) indicates that this is most likely due to the partial or complete 
internal localization αSMA and GFAP. While these probes could be used with good 
success when sorting was carried out on fixed and permeabilized samples, fixation can 
significantly degrade RNA, rendering it useless for qPCR analysis [179]. Unfortunately, a 
set of three externally located, distinct cell marker antibodies that were also conjugated to 
spectrally distinct fluorophores was unavailable during the course of experimentation. For 
future experimentation we recommend the use of multiple antibodies per cell type so that 
the distinct combinations of a certain set of fluorophores could be used to gate for live 
 106 
sorting, rather than a single fluorophore or the modification of the RNA extraction and 
purification protocols to facilitate processing of fixed samples [180]. 
 
Figure 30. Live staining requires distinctly tagged extracellularly located proteins as 
antibody targets. Histograms from a test sort of all three cell types are presented with 
stained (red) and unstained peaks (green) indicated. HBMEC staining was successful, as 
indicated by a peak shift into the stained region of the histogram after staining. HBVP 
staining yielded split peaks potentially due to partial endocytosis of the antibody by the 
HBVPs before FACS.  HA staining was completely ineffective due to the internal 
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